<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Open Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Open Biol</journal-id>
<journal-id journal-id-type="publisher-id">RSOB</journal-id>
<journal-id journal-id-type="hwp">royopenbio</journal-id>
<journal-title-group>
<journal-title>Open Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-2441</issn>
<publisher>
<publisher-name>The Royal Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30518638</article-id>
<article-id pub-id-type="pmc">6303784</article-id>
<article-id pub-id-type="doi">10.1098/rsob.180165</article-id>
<article-id pub-id-type="publisher-id">rsob180165</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>133</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Special Feature</subject>
</subj-group>
<subj-group subj-group-type="leader">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Insights into GABA<sub>A</sub>ergic system alteration in Huntington's disease</article-title>
<alt-title alt-title-type="short">Altered GABAergic signaling in HD</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-8552-131X</contrib-id>
<name>
<surname>Hsu</surname>
<given-names>Yi-Ting</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chang</surname>
<given-names>Ya-Gin</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="aff" rid="af4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chern</surname>
<given-names>Yijuang</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af5">5</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label><institution>PhD Program for Translational Medicine, China Medical University and Academia Sinica</institution>, <country>Taiwan, Republic of China</country></aff>
<aff id="af2"><label>2</label><institution>Department of Neurology, China Medical University Hospital</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan, Republic of China</country></aff>
<aff id="af3"><label>3</label><institution>Institute of Neuroscience, National Yang-Ming University</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan, Republic of China</country></aff>
<aff id="af4"><label>4</label><institution>Taiwan International Graduate Program in Interdisciplinary Neuroscience, National Yang-Ming University and Academia Sinica</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan, Republic of China</country></aff>
<aff id="af5"><label>5</label><institution>Institute of Biomedical Sciences, Academia Sinica</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan, Republic of China</country></aff>
<author-notes>
<corresp id="cor1">e-mail: <email>bmychern@ibms.sinica.edu.tw</email></corresp>
<fn fn-type="other">
<p>A contribution to the special collection commemorating the 90th anniversary of Academia Sinica.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>5</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>5</day>
<month>12</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>8</volume>
<issue>12</issue>
<elocation-id>180165</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 The Authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>Published by the Royal Society under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="rsob-8-180165.pdf"></self-uri>
<self-uri content-type="reviewer_comments" xlink:href="rsob180165_review_history.pdf"></self-uri>
<self-uri xlink:href="rsob180165.thumb.gif" xlink:role="icon"></self-uri>
<abstract>
<p>Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disease that is characterized by a triad of motor, psychiatric and cognitive impairments. There is still no effective therapy to delay or halt the disease progress. The striatum and cortex are two particularly affected brain regions that exhibit dense reciprocal excitatory glutamate and inhibitory gamma-amino butyric acid (GABA) connections. Imbalance between excitatory and inhibitory signalling is known to greatly affect motor and cognitive processes. Emerging evidence supports the hypothesis that disrupted GABAergic circuits underlie HD pathogenesis. In the present review, we focused on the multiple defects recently found in the GABAergic inhibitory system, including altered GABA level and synthesis, abnormal subunit composition and distribution of GABA<sub>A</sub> receptors and aberrant GABA<sub>A</sub> receptor-mediated signalling. In particular, the important role of cation–chloride cotransporters (i.e. NKCC1 and KCC2) is discussed. Recent studies also suggest that neuroinflammation contributes significantly to the abnormal GABAergic inhibition in HD. Thus, GABA<sub>A</sub> receptors and cation–chloride cotransporters are potential therapeutic targets for HD. Given the limited availability of therapeutic treatments for HD, a better understanding of GABAergic dysfunction in HD could provide novel therapeutic opportunities.</p>
</abstract>
<kwd-group>
<kwd>Huntington's disease</kwd>
<kwd>GABAergic signalling</kwd>
<kwd>GABA<sub>A</sub> receptors</kwd>
<kwd>cation–chloride cotransporter</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>China Medical University Hospital</institution>
</institution-wrap>
</funding-source>
<award-id>CRS-106-060</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>December 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Introduction</title>
<p>Huntington's disease (HD) is a progressive and autosomal dominant neurodegenerative disorder that is caused by a CAG repeat expansion in exon 1 of the huntingtin (<italic>htt)</italic> gene on the short arm of chromosome 4. This expansion encodes an expanded polyglutamine stretch in the Huntingtin (HTT) protein [<xref ref-type="bibr" rid="RSOB180165C1">1</xref>]. The clinical manifestations of HD include movement dysfunction, cognitive decline and psychiatric disorders, with great variation between patients. It has been well established that the age of disease onset is greatly affected by the lengths of the CAG repeats, genetic modifiers and environmental stresses [<xref ref-type="bibr" rid="RSOB180165C2">2</xref>–<xref ref-type="bibr" rid="RSOB180165C4">4</xref>]. When the CAG repeat number is 40 or higher, nearly full penetrance is expected. The mean age of onset is 40 years, and the illness duration is 15–20 years from the time of symptomatic onset. Neuronal intranuclear inclusions of mutant HTT protein are the characteristic neuropathology of HD, and these inclusions cause extensive cell loss throughout the brain, especially the striatum and cortex.</p>
<p>Gamma-amino butyric acidergic (GABAergic) projecting neurons of the dorsal striatum and glutamatergic pyramidal neurons of the cortex constitute the corticostriatal pathway [<xref ref-type="bibr" rid="RSOB180165C5">5</xref>], and these neurons are the most affected neurons in HD [<xref ref-type="bibr" rid="RSOB180165C6">6</xref>]. Conversely, GABAergic interneurons in these brain areas are relatively spared [<xref ref-type="bibr" rid="RSOB180165C7">7</xref>]. The balance between the excitatory glutamatergic system and the inhibitory GABAergic system is critical for motor and behaviour control. Dysfunction of this circuit could lead to the development of HD symptoms [<xref ref-type="bibr" rid="RSOB180165C8">8</xref>]. The neurons most vulnerable to the toxicity caused by mutant HTT are the medium spiny neurons (MSNs) that project to the globus pallidus externa as part of the indirect basal ganglia pathway [<xref ref-type="bibr" rid="RSOB180165C9">9</xref>,<xref ref-type="bibr" rid="RSOB180165C10">10</xref>]. The death of these MSNs leads to a disinhibition of the thalamus and hyperactivation of the direct basal ganglia pathway, which subsequently causes involuntary movements (i.e. chorea). As disease progresses, the involvement of cell loss or dysfunction in other regions of the brain, including the thalamus and cerebral cortex, could cause cognitive deficits and mood disorders [<xref ref-type="bibr" rid="RSOB180165C11">11</xref>]. No therapy is currently available to delay the onset or slow disease progression for patients with HD.</p>
<p>Dysfunction of the glutamatergic pathway and the subsequent excitotoxicity were investigated extensively in HD [<xref ref-type="bibr" rid="RSOB180165C12">12</xref>–<xref ref-type="bibr" rid="RSOB180165C14">14</xref>]. Emerging evidence of GABAergic dysfunction was noted in HD. The present manuscript reviews these recent findings on GABAergic dysfunction in HD and discusses the possibility that GABAergic dysfunction may contribute significantly to HD pathogenesis. Further understanding of the abnormal regulation of the important components involved in GABAergic dysfunction may pave the way for the future development of novel therapeutic treatments for HD.</p>
</sec>
<sec id="s2">
<label>2.</label>
<title>Overview of GABAergic signalling</title>
<p>Three aspects of the GABAergic system are discussed in this section: (i) the production, release, reuptake and metabolism of GABA; (ii) GABA receptors; and (iii) the actions of GABA (<xref ref-type="fig" rid="RSOB180165F1">figure 1</xref>).
<fig id="RSOB180165F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>An overview of the γ-aminobutyric acid (GABA) signalling system. (<italic>a</italic>) GABA homeostasis is regulated by neurons and astrocytes. GABA is synthesized by GAD65/67 from glutamate in neurons, while astrocytic GABA is synthesized through MAOB. The release of GABA is mediated by membrane depolarization in neurons and Best1 in astrocytes. The reuptake of GABA is mediated through GAT1 in neurons and GAT3 in astrocytes. The metabolism of GABA is mediated by GABA-T in neurons and astrocytes. The reuptake of GABA in astrocytes is further transformed into glutamine via the TCA cycle and glutamine synthetase (GS). The glutamine is then transported to neurons and converted to glutamate for regeneration of GABA. (<italic>b</italic>) GABA<sub>A</sub> receptors are heteropentameric complexes assembled from 19 different subunits. The compositions of different subunits determines the subcellular distributions and functional properties of the receptors. Phasic inhibition is mediated via the activation of synaptic GABA<sub>A</sub> receptors following brief exposure to a high concentration of extracellular GABA. Tonic inhibition is mediated via the activation of extrasynaptic GABA<sub>A</sub> receptors by a low concentration of ambient GABA. (<italic>c</italic>) The excitatory or inhibitory response of GABA is driven by the chloride gradient across cell membranes, which can be determined via two cation–chloride cotransporters (NKCC1 and KCC2). The high expression of NKCC1 during the developmental stage maintains higher intracellular [Cl<sup>−</sup>] via chloride influx to the cell. The activation of GABA<sub>A</sub> receptors at an early developmental stage results in an outward flow of chloride and an excitatory GABAergic response. As neurons mature, the high expression of KCC2 maintains lower intracellular [Cl<sup>−</sup>] via chloride efflux out of the cell. The activation of GABA<sub>A</sub> receptors on mature neurons results in the inward flow of chloride and an inhibitory GABAergic response.</p></caption><graphic xlink:href="rsob-8-180165-g1"></graphic></fig></p>
<p>GABA is the principal inhibitory neurotransmitter in adult brains. Both neurons and astrocytes can synthesize GABA and release it to activate GABA receptors on neighbouring neurons. Neuronal GABA is synthesized by two glutamic acid decarboxylases (GAD65 and GAD67) from <sc>l</sc>-glutamate. Intracellular GABA is transported into synaptic vesicles via the vesicular GABA transporter (VGAT), and then released into the synapse following membrane depolarization [<xref ref-type="bibr" rid="RSOB180165C15">15</xref>]. Astrocytic GABA is synthesized by monoamine oxidase B (MAOB) and released by the bestrophin 1 (Best1) anion channel when there is a strong electrochemical gradient that drives GABA efflux [<xref ref-type="bibr" rid="RSOB180165C16">16</xref>,<xref ref-type="bibr" rid="RSOB180165C17">17</xref>]. Released GABA regulates neural function via binding to GABA receptors, which are localized either pre- or postsynaptically. GABA signals are terminated by reuptake from the synapse into neuron or astrocyte by several membrane-bound GATs. GAT1 is generally considered the primary presynaptic neuronal GABA transporter [<xref ref-type="bibr" rid="RSOB180165C18">18</xref>], while GAT3 is localized exclusively on astrocytic processes in the cerebral cortex [<xref ref-type="bibr" rid="RSOB180165C19">19</xref>]. In both neurons and astrocytes, GABA is metabolized by GABA transaminase (GABA-T). The glutamate/GABA–glutamine cycle is an important metabolite shuttle between neurons and astrocytes, and it facilitates neurotransmitter homeostasis at GABAergic synapses [<xref ref-type="bibr" rid="RSOB180165C20">20</xref>]. Notably, astrocytes take up GABA and metabolize it into α-ketoglutarate and then glutamate via the tricarboxylic acid (TCA) cycle. The glutamate is further converted to glutamine by glutamine synthetase (GS) and then transported to neurons. In neurons, glutamate is regenerated by phosphate-activated glutaminase (PAG) from glutamine and used by GAD as a substrate to produce GABA.</p>
<p>There are two different types of GABA receptors, ionotropic GABA<sub>A</sub> receptors and metabotropic GABA<sub>B</sub> receptors, which are responsible for fast and slow inhibition, respectively [<xref ref-type="bibr" rid="RSOB180165C15">15</xref>]. GABA<sub>A</sub> receptors are ligand-gated ion channels that are primarily permeable for chloride ions. These receptors are heteropentameric complexes assembled from 19 different subunits (α<sub>1–6</sub>, β<sub>1–3</sub>, γ<sub>1–3</sub>, δ, ɛ, θ, π and ρ<sub>1–3</sub>) [<xref ref-type="bibr" rid="RSOB180165C21">21</xref>,<xref ref-type="bibr" rid="RSOB180165C22">22</xref>]. Most GABA<sub>A</sub> receptors exhibit a 2α : 2β : 1γ composition, which determines the subcellular distribution and functional properties. GABA<sub>A</sub> receptors containing α<sub>1–3</sub>, β<sub>2/3</sub> and γ<sub>2</sub> subunits are mainly synaptic, whereas α<sub>4–6</sub>- and δ-containing receptors are mainly peri- or extrasynaptically distributed [<xref ref-type="bibr" rid="RSOB180165C23">23</xref>]. Two types of GABA<sub>A</sub> receptor-mediated signalling can be discerned, phasic and tonic inhibition [<xref ref-type="bibr" rid="RSOB180165C24">24</xref>]. Phasic inhibition is mediated via activation of synaptic GABA<sub>A</sub> receptors following brief exposure to a high concentration of GABA released from presynaptic vesicles. Conversely, tonic inhibition is mediated via activation of extrasynaptic GABA<sub>A</sub> receptors by a low concentration of ambient GABA. GABA<sub>B</sub> receptors are members of the G-protein-coupled receptor family. GABA<sub>B</sub> receptors are dimers composed of one R1 subunit (R1a or R1b isoforms) and the R2 subunit, which are located pre- and postsynaptically. GABA<sub>B</sub> receptors can transduce signals via intracellular second messengers to modulate the functions of channels and receptors [<xref ref-type="bibr" rid="RSOB180165C25">25</xref>,<xref ref-type="bibr" rid="RSOB180165C26">26</xref>]. To date, there has been no evidence to suggest that GABAergic signals mediated by GABA<sub>B</sub> receptors are altered during HD progression. Therefore, no discussion on GABA<sub>B</sub> receptors is included in the present review.</p>
<p>The strength and polarity of GABA<sub>A</sub> receptor-mediated neuronal inhibition is determined by intracellular chloride concentrations, which are mainly controlled by two cation–chloride cotransporters: K–Cl cotransporter (KCC2) and Na–K–2Cl cotransporter (NKCC1) [<xref ref-type="bibr" rid="RSOB180165C27">27</xref>–<xref ref-type="bibr" rid="RSOB180165C29">29</xref>]. During late embryonic and early postnatal stages, GABA induces depolarizing responses that are important for neurite outgrowth, synaptogenesis and neural plasticity. This response occurs because NKCC1 is highly expressed in immature neurons and enables significant chloride influx and a high concentration of intracellular chloride. Activation of GABA<sub>A</sub> receptors thus causes the efflux of chloride in immature neurons and evokes a depolarizing signal. As neurons mature, NKCC1 is downregulated, and KCC2 is upregulated, and both channels contribute to intracellular chloride concentration regulation and the switching of GABA signals from depolarizing to hyperpolarizing.</p>
</sec>
<sec id="s3">
<label>3.</label>
<title>Role of GABA<sub>A</sub>ergic signalling in mice and humans with HD</title>
<p>Accumulating evidence demonstrates that the GABAergic system, especially GABA<sub>A</sub> receptor-mediated signalling (<xref ref-type="table" rid="RSOB180165TB1">table 1</xref>), is altered in the brains of several mouse models of HD, such as R6/2 [<xref ref-type="bibr" rid="RSOB180165C41">41</xref>] and R6/1 mice [<xref ref-type="bibr" rid="RSOB180165C42">42</xref>], N171-82Q [<xref ref-type="bibr" rid="RSOB180165C43">43</xref>], YAC 128 [<xref ref-type="bibr" rid="RSOB180165C44">44</xref>] and BACHD transgenic mice [<xref ref-type="bibr" rid="RSOB180165C45">45</xref>], Hdh knock-in mice [<xref ref-type="bibr" rid="RSOB180165C46">46</xref>], conditional HD mice [<xref ref-type="bibr" rid="RSOB180165C35">35</xref>], and HD patients. Note that a more focused review about HD-related changes in the expression of GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) has been published recently [<xref ref-type="bibr" rid="RSOB180165C47">47</xref>]. Therefore, a dysregulated GABAergic system is an authentic symptom of HD, and it may contribute significantly to HD pathogenesis. Because the striatum and cortex are the two most affected brain areas in HD, alteration of the GABA<sub>A</sub>ergic system was actively investigated in these two brain areas.
<table-wrap id="RSOB180165TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Changes in GABA<sub>A</sub> receptors and related molecules in Huntington's disease. ChAT-IN, choline acetyltransferase positive-interneuron; GAD, glutamic acid decarboxylase; IPSC, inhibitory postsynaptic currents; KCC2, K–Cl cotransporter; mo, months; MSN, medium-sized spiny projection neuron; NKCC1, Na–K–2Cl cotransporter; p't, patient; PPV-IN, parvalbumin-interneuron; VGAT, vesicular GABA transporter; wks, weeks.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th colspan="1" rowspan="1"></th><th align="left" colspan="1" rowspan="1">disease stage</th><th align="left" colspan="1" rowspan="1">mRNA expression<sup>a</sup></th><th align="left" colspan="1" rowspan="1">protein expression<sup>a</sup></th><th align="left" colspan="1" rowspan="1">functional<sup>b</sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="2">cortex</td><td colspan="1" rowspan="1">late stage</td><td colspan="1" rowspan="1">↓α<sub>1</sub> (R6/2 mice, 12 wks; N171-82Q mice, 16 wks; prefrontal cortex of HD p't)<break></break>↔α<sub>2</sub>, α<sub>3</sub> (R6/2 mice, 12 wks)<break></break>↓α<sub>2</sub> (<italic>Hdh</italic><sup>150Q</sup> mice, 15 mo; prefrontal cortex of HD p't)<break></break>↓α<sub>4</sub> (R6/2 mice, 12 wks)<break></break>↓δ (R6/2 mice, 12 wks; N171-82Q mice, 16 wks; <italic>Hdh</italic><sup>150Q</sup> mice, 15 mo; prefrontal cortex of HD p't)<break></break>↓GAD67 (R6/2 mice, 12wks)<break></break>↓KCC2 (<italic>Hdh</italic><sup>150Q</sup> mice, 15 mo)</td><td colspan="1" rowspan="1">↓δ (R6/2 mice, 12 wks)<break></break>↓KCC2 (R6/2 mice, 12 wks; N171-82Q mice, 16wks)<break></break>↑NKCC1 (R6/2 mice, 12 wks)</td><td colspan="1" rowspan="1">↓IPSC (pyramidal neurons, R6/2 mice, 80 days; N171-82Q mice, 4 mo; BACHD mice, 6 mo; conditional HD mice, 6 mo)<break></break>↑IPSC (pyramidal neurons, YAC128 mice, 12 mo; Hdh (CAG)150 mice, 12 mo)</td></tr><tr><td colspan="1" rowspan="1">early stage</td><td colspan="1" rowspan="1">↔α<sub>1–3</sub> (R6/2 mice, 7 wks)<break></break>↓α<sub>4</sub> (R6/2 mice, 7 wks)<break></break>↓δ (R6/2 mice, 7 wks)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">↑IPSC (pyramidal neurons, R6/2 mice, 40 days; YAC128 mice, 6 mo)<break></break>↔IPSC (pyramidal neurons, N171-82Q mice, 1–2 mo; BACHD mice, 3 mo)</td></tr><tr><td colspan="1" rowspan="1">striatum</td><td colspan="1" rowspan="1">late stage</td><td colspan="1" rowspan="1">↓α<sub>2</sub> (R6/2 mice, 12 wks; <italic>Hdh</italic><sup>150Q</sup> mice,15 mo; R6/1 mice, 6 mo)<break></break>↑α<sub>3</sub> (R6/2 mice, 12 wks; R6/1 mice, 6 mo)<break></break>↓α<sub>4</sub> (R6/2 mice, 12 wks; R6/1 mice, 6 mo)<break></break>↑α<sub>5</sub> (YAC128 mice, 12 mo; R6/1 mice, 6 mo)<break></break>↔β<sub>1–3</sub> (R6/1 mice, 6 mo)<break></break>↑β<sub>3</sub> (YAC128 mice, 12 mo)<break></break>↑γ<sub>1</sub> (R6/1 mice, 6 mo)<break></break>↔γ<sub>2</sub> (R6/1 mice, 6 mo)<break></break>↓δ (R6/2 mice, 12 wks; N171-82Q, 16wks; <italic>Hdh</italic><sup>150Q</sup> mice, 15 mo; R6/1 mice, 6 mo; caudate of HD p't)<break></break>↑δ (YAC128 mice, 12 mo)<break></break>↓GAD67 (R6/1 mice, 6 mo)</td><td colspan="1" rowspan="1">↑α<sub>1</sub> (MSN, R6/1 mice, 6 mo; <italic>Hdh</italic><sup>111Q</sup>, 8 mo)<break></break>↓α<sub>1</sub> (PV-IN, R6/1 mice, 6 mo; putamen of HD p't)<break></break>↓α<sub>2</sub> (MSN, PV-IN, R6/1 mice, 6 mo)<break></break>↑α<sub>3</sub> (MSN, ChAT-IN, R6/1 mice, 6 mo)<break></break>↑α<sub>5</sub> (R6/1 mice, 6 mo; <italic>Hdh</italic><sup>111Q</sup>, 8 mo)<break></break>↔β<sub>2–3</sub> (R6/1 mice, 6mo)<break></break>↓β<sub>2/3</sub> (N171-82Q, 4 mo; putamen of HD p't)<break></break>↔γ<sub>2</sub> (R6/1 mice, 6 mo)<break></break>↓γ<sub>2</sub> (putamen of HD p't)<break></break>↓δ (R6/2 mice, 12 wks; R6/1 mice, 6 mo)<break></break>↔GAD65/67 (R6/2 mice, 12 wks, R6/1 mice, 6 mo)<break></break>↑GAD65 (<italic>Hdh</italic><sup>111Q</sup>, 8 mo)<break></break>↔VGAT (R6/1 mice, 6 mo)<break></break>↔NL2, or gephyrin (R6/1 mice, 6 mo)<break></break>↓KCC2 (R6/2 mice, 12 wks; N171-82Q mice, 16 wks)<break></break>↑NKCC1 (R6/2 mice, 12 wks; <italic>Hdh</italic><sup>150Q</sup> mice, 15 mo; GFAP-HD mice, 18–24 mo)</td><td colspan="1" rowspan="1">↑IPSC (D2-MSN, R6/2 mice, greater than 60 days; MSN, Hdh(CAG)150 mice, 12 mo; YAC128 mice, 12 mo)<break></break>↓IPSC (MSN, N171-82Q mice, 4mo)<break></break>↓tonic current (D2-MSN, R6/2 mice, greater than 60 days; MSN, Q175 mice, greater than 1 yr)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">early stage</td><td colspan="1" rowspan="1">↔α<sub>1–3</sub> (R6/2 mice, 7 wks)<break></break>↓α<sub>4</sub> (R6/2 mice, 7 wks)<break></break>↓α<sub>5</sub> (YAC128 mice, 6 mo)<break></break>↓β<sub>3</sub> (YAC128 mice, 6 mo)<break></break>↓δ (R6/2 mice, 7 wks)<break></break>↑δ(YAC128 mice, 6 mo)</td><td colspan="1" rowspan="1">↔α<sub>1,3,5</sub> (R6/1 mice, 2 mo)<break></break>↑α<sub>2</sub> (MSN, PV-IN, R6/1 mice, 2 mo)<break></break>↑β<sub>2</sub> (R6/1 mice, 2 mo)<break></break>↔β<sub>3</sub> (R6/1 mice, 2 mo)<break></break>↔GAD65/67, VGAT (R6/1 mice, 2 mo)<break></break>↔NL2, or gephyrin (R6/1 mice, 2mo)<break></break>↔NKCC1 (R6/2 mice, 7 wks)</td><td colspan="1" rowspan="1">↔IPSC (MSN, N171-82Q mice, 1–2 mo; BACHD, 3 mo)<break></break>↑IPSC (MSN, YAC128 mice, 1 mo)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>mRNA and protein expressions of the indicated molecules are summarized from the following references [<xref ref-type="bibr" rid="RSOB180165C30">30</xref>–<xref ref-type="bibr" rid="RSOB180165C34">34</xref>].</p></fn><fn><p><sup>b</sup>Electrophysiological studies in the striatal and cortical neurons are summarized from the following references [<xref ref-type="bibr" rid="RSOB180165C33">33</xref>,<xref ref-type="bibr" rid="RSOB180165C35">35</xref>–<xref ref-type="bibr" rid="RSOB180165C40">40</xref>].</p></fn></table-wrap-foot></table-wrap></p>
<sec id="s3a">
<label>3.1.</label>
<title>Alterations in GABA levels and metabolism</title>
<p>Earlier studies using postmortem brain tissues from HD patients revealed that HD patients have a lower GABA content in the caudate/putamen and cortex than non-HD subjects [<xref ref-type="bibr" rid="RSOB180165C48">48</xref>–<xref ref-type="bibr" rid="RSOB180165C51">51</xref>]. It remains elusive whether HD patients have lower activity of GAD, an enzyme responsible for the production of GABA [<xref ref-type="bibr" rid="RSOB180165C52">52</xref>,<xref ref-type="bibr" rid="RSOB180165C53">53</xref>]. R6/2 and R6/1 mice have lower levels of GAD67 mRNA in the cortex and striatum, respectively, than their littermate controls [<xref ref-type="bibr" rid="RSOB180165C30">30</xref>,<xref ref-type="bibr" rid="RSOB180165C54">54</xref>]. Neurons differentiated from HD induced pluripotent stem cells (iPSCs) also contain fewer GAD67 transcripts than control iPSCs [<xref ref-type="bibr" rid="RSOB180165C55">55</xref>]. In addition, a recent study of metabolic profiling in R6/2 mice at a symptomatic stage revealed significant decreases in GABA synthesis in the cortex and striatum using <sup>13</sup>C labelling and mass spectrometry [<xref ref-type="bibr" rid="RSOB180165C56">56</xref>]. Overall, these studies suggest a trend of reduced GABA in HD. Whether other components involved in GABA metabolism, such as GABA transporters (GAT1, GAT3), enzymes for GABA degradation (e.g. GABA-T) or channels for glia GABA release (Best1), are affected during HD progression is not known.</p>
</sec>
<sec id="s3b">
<label>3.2.</label>
<title>Alterations in the subunit composition and distribution of GABA<sub>A</sub> receptors</title>
<p>When compared with that of non-HD subjects, a significant loss of GABA<sub>A</sub>R binding sites in the caudate of HD patients has been reported [<xref ref-type="bibr" rid="RSOB180165C31">31</xref>,<xref ref-type="bibr" rid="RSOB180165C57">57</xref>–<xref ref-type="bibr" rid="RSOB180165C59">59</xref>]. In particular, the levels of α and/or γ subunits that constitute the benzodiazepine-binding sites of GABA<sub>A</sub>R are reduced. Changes in the protein and mRNA levels of GABA<sub>A</sub> receptor subunits were also observed in the brains of mice and humans with HD [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>–<xref ref-type="bibr" rid="RSOB180165C34">34</xref>,<xref ref-type="bibr" rid="RSOB180165C54">54</xref>,<xref ref-type="bibr" rid="RSOB180165C60">60</xref>,<xref ref-type="bibr" rid="RSOB180165C61">61</xref>]. Immunohistochemistry staining revealed that the putamen of HD patients contained lower levels of α<sub>1</sub>, β<sub>2,3</sub> and γ<sub>2,</sub> but not α<sub>3</sub> subunits than non-HD subjects [<xref ref-type="bibr" rid="RSOB180165C60">60</xref>]. Consistently, we had reported a significant decrease in the transcripts of GABA<sub>A</sub>R α<sub>1</sub>, α<sub>2</sub> and δ, but not α<sub>3</sub> mRNA in the postmortem prefrontal cortex of HD patients. A trend towards lower levels of α<sub>2</sub> and δ subunit transcripts in the postmortem caudate of HD patients was also found. Different HD mouse models (R6/2, N171-82Q and Hdh CAG knock-in mice) recapitulated these findings at the manifest stage [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>]. Reduction of α<sub>4</sub> and δ subunits, which are located mainly perisynaptically and extrasynaptically, can be observed as early as the premanifest stage in the cortex and striatum of HD mice. The α<sub>4</sub><italic>βδ</italic> subunit-containing GABA<sub>A</sub>Rs mainly mediate tonic conductance in adult cortical pyramidal cells and striatal medium spiny neurons [<xref ref-type="bibr" rid="RSOB180165C23">23</xref>,<xref ref-type="bibr" rid="RSOB180165C36">36</xref>]. The reduced cortical and striatal α<sub>4</sub> and δ subunits may result in poor GABAergic tonic inhibition in the early stages of HD, and this likely precedes the appearance of overt symptoms. Interestingly, another group reported that the levels of α<sub>1</sub>, α<sub>3</sub> and α<sub>5</sub> subunit mRNAs and proteins are increased in the striatum at the manifest stage in R6/1 mice, and the levels of the δ subunit are decreased. No change in the levels of these subunits was observed before the onset of motor symptoms in R6/1 mice [<xref ref-type="bibr" rid="RSOB180165C54">54</xref>]. These authors further demonstrated changes in GABA<sub>A</sub>R subunits in different subtypes of striatal neurons using immunohistochemical staining. They found that the expression level of the α<sub>1</sub> subunit increased in MSNs and decreased in parvalbumin (PV)-expressing interneurons. Moreover, the α<sub>2</sub> subunit in PVs and MSNs was decreased, while the α<sub>3</sub> subunit was increased in the choline acetyltransferase (ChAT)-expressing interneurons at the manifest stage in R6/1 mice. In an HD mouse model (N171-82Q) where mHTT is expressed mainly in neurons, a significant decrease in the surface expression of GABA<sub>A</sub>R β<sub>2/3</sub> subunits at the manifest stage was reported. This defect occurs because of the disrupted GABA<sub>A</sub>R trafficking but there is no change in total amount [<xref ref-type="bibr" rid="RSOB180165C34">34</xref>]. No change in the mRNA or protein expression level of total β<sub>2</sub>, β<sub>3</sub> or γ<sub>2</sub> subunits was found in R6/1 mice [<xref ref-type="bibr" rid="RSOB180165C54">54</xref>]. No major changes were found in the expression levels of neuroligin or gephyrin proteins, which are involved in the targeting and clustering of GABA<sub>A</sub> receptors at the postsynaptic membrane in R6/1 mice [<xref ref-type="bibr" rid="RSOB180165C54">54</xref>]. Rosas-Arellano <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB180165C61">61</xref>] recently reported an altered expression of peri- or extrasynaptically distributed GABA<sub>A</sub> tonic subunits (α<sub>5</sub>, β<sub>3</sub>, δ and ρ<sub>2</sub>) in the D2 dopamine receptor (D2R)-enriched neostriatal pathway, and their relocalization into the synaptic cleft during the early stage in YAC128 mice. These authors suggested that the intrasynaptic localization of GABA<sub>A</sub> tonic subunits was a cellular strategy to compensate for the inferior GABA environment in the HD neostriatum and facilitate the GABA-mediated inhibition. The aforementioned changes in subunit composition and distribution of GABA<sub>A</sub> receptors suggest that the GABA-mediated phasic or tonic inhibition may be altered.</p>
<p>GABAergic transmission in cortical and striatal neurons during HD progression has been investigated using electrophysiological approaches in several HD mouse models (R6/2, N171-82Q, YAC128, BACHD, Hdh CAG knock-in mice and conditional HD mice) [<xref ref-type="bibr" rid="RSOB180165C34">34</xref>,<xref ref-type="bibr" rid="RSOB180165C35">35</xref>,<xref ref-type="bibr" rid="RSOB180165C37">37</xref>–<xref ref-type="bibr" rid="RSOB180165C40">40</xref>,<xref ref-type="bibr" rid="RSOB180165C62">62</xref>]. Both increases and decreases in GABA<sub>A</sub> receptor-mediated synaptic currents in cortical pyramidal neurons and striatal neurons have been reported in different HD mouse models. Importantly, the GABA<sub>A</sub> receptor-mediated tonic chloride current in striatal neurons is consistently reduced in two HD mouse models (R6/2 and Q175) [<xref ref-type="bibr" rid="RSOB180165C39">39</xref>,<xref ref-type="bibr" rid="RSOB180165C40">40</xref>]. Reduced tonic GABA current is observed in D2R-expressing MSNs in R6/2 mice. Because the striatal tonic GABA<sub>A</sub> currents have been proposed to have a neuroprotective effect against excitotoxicity [<xref ref-type="bibr" rid="RSOB180165C63">63</xref>], the reduced tonic GABA<sub>A</sub> currents may contribute to the elevated susceptibility of the D2R-expressing MSNs in HD. Moreover, deficits in GABA-mediated cortical inhibition have been reported in premanifest and early HD patients measured by a transcranial magnetic stimulation approach. The impaired cortical inhibition in HD patients is likely to associate with disease severity, psychiatric performance and neurocognitive disturbances [<xref ref-type="bibr" rid="RSOB180165C64">64</xref>]. Taken together, these studies provide strong evidence to support that alterations in GABA<sub>A</sub> receptor-mediated tonic and phasic inhibitory transmission occur in HD and may contribute to HD pathogenesis.</p>
</sec>
<sec id="s3c">
<label>3.3.</label>
<title>Is GABA an inhibitory or excitatory neurotransmitter?</title>
<p>The reversal potential for GABA<sub>A</sub>-mediated currents is controlled by the two chloride cotransporters, KCC2 and NKCC1. In the cortex and striatum of different HD mouse models, expression of KCC2 and an interacting protein, the brain-type creatine kinase (CKB), is reduced [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>]. The interaction between KCC2 and CKB in HD brains is also lower than in their littermate controls. Because the activity of KCC2 is positively controlled by CKB [<xref ref-type="bibr" rid="RSOB180165C65">65</xref>,<xref ref-type="bibr" rid="RSOB180165C66">66</xref>] and the expression and activity of CKB are reduced in HD [<xref ref-type="bibr" rid="RSOB180165C67">67</xref>,<xref ref-type="bibr" rid="RSOB180165C68">68</xref>], the function of KCC2 in HD is likely lower, which may subsequently reduce GABA<sub>A</sub>-mediated inhibitory function. Conversely, NKCC1 expression in the striatum of several HD mouse models (R6/2 mice, N171-82Q and Hdh CAG knock-in mice) is abnormally elevated at the symptomatic stage (Y-T Hsu, Y-G Chang, Y-C Li, K-Y Wang, H-M Chen, D-J Lee, C-H Tsai, C-C Lien, Y Chern 2018, personal communication). Consistently, a depolarized GABAergic response in the striatal neurons of R6/2 mice was observed by a gramicidin-perforated patch-clamp recording, which may reduce the driving force or even reverse the chloride flow following activation of GABA<sub>A</sub> receptors. Under this impaired condition, stimulation of GABAergic neurons in the striatum of HD mice might become excitatory.</p>
<p>Moreover, Dargaei <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB180165C69">69</xref>] have shown that alterations in the cation–chloride cotransporters also occurred in the hippocampus of two HD mouse models (R6/2 and YAC128). These authors reported that reduced KCC2 expression and an increase in NKCC1 expression converted the GABA-mediated stimulation from inhibitory to excitatory in the hippocampus. These studies collectively support the hypothesis that abnormally reduced GABAergic inhibition underlies HD pathogenesis.</p>
<p>Accumulating evidence also suggested that the upregulation of NKCC1 and a downregulation of KCC2 level in epileptogenic regions (such as the hippocampus) increase the susceptibility of developing seizures in rodents and humans [<xref ref-type="bibr" rid="RSOB180165C70">70</xref>,<xref ref-type="bibr" rid="RSOB180165C71">71</xref>]. In line with this concept, R6/2 mice with anomalous levels of NKCC1 and KCC2 in the hippocampus are more susceptible to the development of seizures [<xref ref-type="bibr" rid="RSOB180165C72">72</xref>]. R6/2 mice, a well-established early onset and rapidly progressive transgenic mouse model carrying exon 1 of the HD gene with approximately 130 CAG repeats [<xref ref-type="bibr" rid="RSOB180165C41">41</xref>], may capture certain features of juvenile-onset HD patients. Notably, seizures were present in 30–40% of juvenile HD patients and were more likely to occur with earlier disease onset and large CAG expansions (greater than 80 CAG repeats) [<xref ref-type="bibr" rid="RSOB180165C73">73</xref>,<xref ref-type="bibr" rid="RSOB180165C74">74</xref>]. In contrast to the R6 lines of HD mice, seizures are not present in another early onset HD mouse model, N171-82Q mice, which carry a cDNA fragment encoding an N-terminal fragment of HTT with 82 glutamines and express mHTT only in neurons [<xref ref-type="bibr" rid="RSOB180165C43">43</xref>]. Full length and knock-in HD mouse models, which capture more features of adult-onset HD patients, do not have seizures [<xref ref-type="bibr" rid="RSOB180165C75">75</xref>]. Seizure is also infrequent or virtually absent in adult-onset HD patients [<xref ref-type="bibr" rid="RSOB180165C74">74</xref>]. These discrepancies regarding seizure occurrence between different mouse models and juvenile- and adult-onset HD are worth further investigation, especially on the involvement of GABAergic dysfunction.</p>
</sec>
</sec>
<sec id="s4">
<label>4.</label>
<title>Molecular mechanism(s) underlying the abnormal GABA<sub>A</sub>ergic system in HD</title>
<p>In HD, misfolded mutant HTT proteins engage in aberrant interactions with multiple cellular components to cause synaptic dysfunction and the degeneration of specific neurons in the brain [<xref ref-type="bibr" rid="RSOB180165C76">76</xref>,<xref ref-type="bibr" rid="RSOB180165C77">77</xref>]. The proposed mechanisms of HD pathogenesis include abnormal protein aggregation and clearance, transcriptional deregulation, impaired axonal transport and vesicle trafficking, mitochondrial toxicity, energy imbalance, oxidative stress, glutamate excitotoxicity and neuroinflammation [<xref ref-type="bibr" rid="RSOB180165C77">77</xref>–<xref ref-type="bibr" rid="RSOB180165C79">79</xref>]. These toxic effects can be mediated through cell-autonomous or cell non-autonomous mechanisms. The potential mechanisms underlying the GABAergic abnormalities are summarized in <xref ref-type="fig" rid="RSOB180165F2">figure 2</xref>.
<fig id="RSOB180165F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Molecular mechanism(s) underlying the abnormal GABA<sub>A</sub>ergic system in HD. (<italic>a</italic>) In the normal condition, adult neurons express high KCC2 and few NKCC1 to maintain the lower intracellular chloride concentration, which results in an inward flow of chloride when GABA<sub>A</sub> receptors are activated. Astrocytes function normally for the homeostasis of glutamate, potassium and glutamate/GABA-glutamine cycle. (<italic>b</italic>) In Huntington's disease, reduced GABA<sub>A</sub> receptor-mediated neuronal inhibition is associated with enhanced NKCC1 expression and a decreased expression in KCC2 and membrane localized GABA<sub>A</sub> receptors. The dysregulated GABA<sub>A</sub>ergic system might be caused by mutant HTT, excitotoxicity, neuroinflammation or other factors. Mutant HTT in neurons alters the transcription of genes (<italic>GABA<sub>A</sub>R</italic> and <italic>KCC2</italic>) through interactions with transcriptional activators (SP1) and repressors (REST/NRSF). Mutant HTT in neurons also disrupts the intracellular trafficking of GABA<sub>A</sub>Rs to the cellular membrane. HD astrocytes have impaired homeostasis of extracellular potassium/glutamate (due to deficits of astrocytic Kir4.1 channel and glutamate transporters, Glt-1) and cause neuronal excitability, which might be related to the changes of KCC2, NKCC1 and GABA<sub>A</sub>R. The activity of KCC2 could be affected through its interacting proteins, such as CKB and mHTT. Neuroinflammation, which is evoked by the interaction of HD astrocyte and microglia, enhances NKCC1 expression in neurons at the transcriptional level through an NF-κB-dependent pathway. HD astrocytes also have compromised astrocytic metabolism of glutamate/GABA–glutamine cycle that contributes to lower GABA synthesis.</p></caption><graphic xlink:href="rsob-8-180165-g2"></graphic></fig></p>
<sec id="s4a">
<label>4.1.</label>
<title>Molecular mechanisms underlying the mutant HTT-mediated suppression of GABA<sub>A</sub> receptors and their downstream signalling molecules</title>
<p>Earlier studies have shown that HTT interacts with many important transcriptional activators and repressors [<xref ref-type="bibr" rid="RSOB180165C80">80</xref>,<xref ref-type="bibr" rid="RSOB180165C81">81</xref>]. Thus, the loss of normal HTT function due to the poly-Q stretch-mediated changes in protein properties or cellular location of HTT is known to dysregulate the global transcriptional profile in HD brains [<xref ref-type="bibr" rid="RSOB180165C80">80</xref>–<xref ref-type="bibr" rid="RSOB180165C82">82</xref>]. For example, mutant HTT inhibits the transcription of genes containing the neuron-restrictive silencer factor (NRSF) by failing to interact with repressor element-1 silencing transcription factor (REST) and forming the nuclear corepressor complex at the RE1/NRSE nuclear site [<xref ref-type="bibr" rid="RSOB180165C81">81</xref>]. In addition, mutant HTT inhibits the transcriptional activator specificity protein 1 (Sp1) binding to DNA and causes the transcriptional inhibition [<xref ref-type="bibr" rid="RSOB180165C80">80</xref>]. Notably, the promoters of GABA<sub>A</sub>R subunits contain NRSE- and Sp1-binding sites [<xref ref-type="bibr" rid="RSOB180165C83">83</xref>]. The <italic>KCC2</italic> gene also includes two RE1/NRSE sites that flank its transcription start site [<xref ref-type="bibr" rid="RSOB180165C84">84</xref>]. Therefore, mutant HTT might interfere with the transcriptional machinery to reduce the expression levels of KCC2 and GABA<sub>A</sub> receptor subunits in HD brains.</p>
<p>HTT also interacts with Huntingtin-associated protein 1 (HAP1), which binds with GABA<sub>A</sub>R and KIF5 (kinesin motor protein 5) for transport to the synapses [<xref ref-type="bibr" rid="RSOB180165C85">85</xref>]. The polyQ-expanded mutant HTT disrupts the HAP1–KIF5 complex, impairs the trafficking of GABA<sub>A</sub>R to the synapse, and reduces the synaptic inhibition in HD brains [<xref ref-type="bibr" rid="RSOB180165C34">34</xref>].</p>
<p>It remains to be determined whether mutant HTT interacts with cation–chloride cotransporters directly or indirectly to affect their function or expression. Two proteomic studies reported a potential association between KCC2 and HTT because the KCC2 protein is highly enriched in the HTT proteome [<xref ref-type="bibr" rid="RSOB180165C86">86</xref>,<xref ref-type="bibr" rid="RSOB180165C87">87</xref>]. The interaction of HTT and KCC2 was demonstrated in the hippocampus of wild-type and HD mice (R6/2) using coimmunoprecipitation assays. No such interaction between NKCC1 and HTT was reported [<xref ref-type="bibr" rid="RSOB180165C69">69</xref>]. Dargaei <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB180165C69">69</xref>] suggested that KCC2 may be sequestered into mutant HTT inclusions, which greatly interfere with the function and availability of KCC2. Another possibility is that HTT might affect the function of KCC2 by interfering with KCC2-interacting proteins, such as CKB (an enzyme involved in energy homeostasis). Consistent with this hypothesis, reduced CKB expression contributes to neuronal dysfunction in HD pathogenesis [<xref ref-type="bibr" rid="RSOB180165C68">68</xref>,<xref ref-type="bibr" rid="RSOB180165C88">88</xref>]. This reduction is very important because KCC2 is positively regulated by CKB via a protein–protein interaction [<xref ref-type="bibr" rid="RSOB180165C65">65</xref>,<xref ref-type="bibr" rid="RSOB180165C66">66</xref>]. In HD neurons, reduced interaction between KCC2 and CKB was demonstrated by a proximity ligation assay [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>].</p>
</sec>
<sec id="s4b">
<label>4.2.</label>
<title>Enhanced neuroinflammation contributes to the altered GABAergic signalling</title>
<p>Previous studies suggest that inflammatory mediators may affect GABAergic signalling via altering the expression of cation–chloride cotransporters, NKCC1 and/or KCC2, to affect chloride homeostasis in models of neuropathic pain [<xref ref-type="bibr" rid="RSOB180165C89">89</xref>,<xref ref-type="bibr" rid="RSOB180165C90">90</xref>].</p>
<p>Reactive gliosis (i.e. accumulation of activated astrocytes and microglia) and neuroinflammation have been observed in the brains of mice and patients with HD, and are known to contribute to neuronal dysfunction. Several reports have indicated that mutant HTT-expressing astrocytes led to the cell death of neurons [<xref ref-type="bibr" rid="RSOB180165C91">91</xref>] and activation of nuclear factor (NF)-κB-mediated inflammatory response [<xref ref-type="bibr" rid="RSOB180165C92">92</xref>]. Emerging evidence indicates that microglial activation is also observed in the brains of HD mouse models and patients [<xref ref-type="bibr" rid="RSOB180165C93">93</xref>–<xref ref-type="bibr" rid="RSOB180165C96">96</xref>]. Abnormally activated microglia and astrocytes result in increased production of inflammatory mediators in HD brains, such as IL1-β, IL-6 and TNF-α [<xref ref-type="bibr" rid="RSOB180165C79">79</xref>,<xref ref-type="bibr" rid="RSOB180165C92">92</xref>–<xref ref-type="bibr" rid="RSOB180165C94">94</xref>,<xref ref-type="bibr" rid="RSOB180165C97">97</xref>]. A recent study reported that activated microglia induce neurotoxic reactive astrocytes by secreting IL-1α, TNF and C1q, and reactive astrocytes cause the neuronal dysfunction in neurodegenerative disorders [<xref ref-type="bibr" rid="RSOB180165C98">98</xref>]. Expression of mutant HTT in astrocytes led to enhanced NKCC1 expression in neurons at the transcriptional level through an NF-κB-dependent pathway (Y-T Hsu, Y-G Chang, Y-C Li, K-Y Wang, H-M Chen, D-J Lee, C-H Tsai, C-C Lien, Y Chern 2018, personal communication). Consistent with the importance of NF-κB, both the mouse and human <italic>NKCC1</italic> promoters have NF-κB binding sites in their promoter region [<xref ref-type="bibr" rid="RSOB180165C99">99</xref>–<xref ref-type="bibr" rid="RSOB180165C101">101</xref>]. In addition, two earlier studies showed that the activity and/or protein expression of NKCC1 was positively regulated by NF-κB [<xref ref-type="bibr" rid="RSOB180165C102">102</xref>,<xref ref-type="bibr" rid="RSOB180165C103">103</xref>]. The aberrant activation of NF-κB-mediated inflammation in mutant HTT-expressing astrocytes likely alters neuronal functions via the cytokine-mediated upregulation of NKCC1 in neurons and changes neuronal responses to GABAergic stimuli.</p>
<p>Notably, neuroinflammation and the GABA neurotransmitter system are reciprocally regulated in the brain (reviewed in [<xref ref-type="bibr" rid="RSOB180165C104">104</xref>,<xref ref-type="bibr" rid="RSOB180165C105">105</xref>]). Specifically, neuroinflammation induces changes in the GABA neurotransmitter system, such as reduced GABA<sub>A</sub> receptor subunit expression, while activation of GABA<sub>A</sub> receptors likely antagonizes inflammation. TNF-α, a proinflammatory cytokine, induces a downregulation of the surface expression of GABA<sub>A</sub>Rs containing α<sub>1</sub>, α<sub>2</sub>, β<sub>2/3</sub> and γ<sub>2</sub> subunits and a decrease in inhibitory synaptic strength in a cellular model of hippocampal neuron culture [<xref ref-type="bibr" rid="RSOB180165C106">106</xref>]. The same group further demonstrated that protein phosphatase 1-dependent trafficking of GABA<sub>A</sub>Rs was involved in the TNF-α evoked downregulation of GABAergic neurotransmission [<xref ref-type="bibr" rid="RSOB180165C107">107</xref>]. Upregulation of TNF-α also negatively impacts the expression of GABA<sub>A</sub>R α<sub>2</sub> subunit mRNA and thus decreases the presynaptic inhibition in the dorsal root ganglion in a rat experimental neuropathic pain model [<xref ref-type="bibr" rid="RSOB180165C108">108</xref>]. Conversely, blockade of central GABA<sub>A</sub>Rs in mice by a GABA<sub>A</sub>R antagonist increased both the basal and restraint stress-induced plasma IL-6 levels [<xref ref-type="bibr" rid="RSOB180165C109">109</xref>]. Inhibition of GABA<sub>A</sub>R activation by picrotoxin increased the nuclear translocation of NF-κB in acute hippocampal slice preparations [<xref ref-type="bibr" rid="RSOB180165C110">110</xref>]. Collectively, neuroinflammation weakens the inhibitory synaptic strength in neurons, at least partly, through the reduction of GABA<sub>A</sub>Rs. The reduced expression and function of GABA<sub>A</sub>Rs may further increase inflammatory responses. It remains elusive whether the same mechanism occurs in the inflammatory environment in HD brains.</p>
</sec>
<sec id="s4c">
<label>4.3.</label>
<title>Other potential mechanisms</title>
<p>Astrocytic factor(s) other than neuroinflammation may also contribute to the impaired GABAergic signalling in HD brains. Activated astrocytes in HD have defects that affect their supportive functions to neurons. For example, HD astrocytes express fewer glutamate transporters than wild-type astrocytes and thus are deficient in astrocytic glutamate homeostasis [<xref ref-type="bibr" rid="RSOB180165C56">56</xref>,<xref ref-type="bibr" rid="RSOB180165C111">111</xref>] and have abnormal extracellular potassium homeostasis due to astrocytic Kir4.1 channel deficits [<xref ref-type="bibr" rid="RSOB180165C112">112</xref>]. The reduced astrocytic glutamate transporters may contribute to glutamate toxicity. Interestingly, excitotoxicity is known to negatively regulate the expression of KCC2 and GABA<sub>A</sub> receptor subunits [<xref ref-type="bibr" rid="RSOB180165C113">113</xref>,<xref ref-type="bibr" rid="RSOB180165C114">114</xref>] and might also affect GABAergic signalling in HD. In addition, Tong <italic>et al</italic>. [<xref ref-type="bibr" rid="RSOB180165C112">112</xref>] reported that Kir4.1 deficiency in astrocytes evokes an elevation in striatal extracellular potassium and causes MSN hyperexcitability in two different HD mouse models (R6/2 and Q175). Another study revealed that disturbed astrocyte-mediated potassium buffering caused hyperactivity of neuronal NKCC1 in ammonia-induced neurotoxicity [<xref ref-type="bibr" rid="RSOB180165C115">115</xref>]. Thus, hyperexcitability resulting from deficiency of astrocytic Kir4.1 might have also contributed to neuronal NKCC1 upregulation and altered GABAergic signalling in HD brains. Moreover, Skotte <italic>et al.</italic> [<xref ref-type="bibr" rid="RSOB180165C56">56</xref>] reported decreased astrocytic glutamine release and compromised astrocytic metabolism of glutamate–GABA–glutamine cycling, which resulted in lower GABA synthesis in the R6/2 mouse model. Thus, astrocytes and their interaction with neurons in HD brains play important roles in GABAergic signalling.</p>
</sec>
</sec>
<sec id="s5">
<label>5.</label>
<title>Potential therapeutic implications in HD</title>
<sec id="s5a">
<label>5.1.</label>
<title>Modulating the GABA<sub>A</sub> receptor as a therapeutic target</title>
<p>In view of the presently discovered HD-related deficit in the GABA system, the question arises whether HD patients can benefit from drugs that stimulate the GABA system (<xref ref-type="fig" rid="RSOB180165F3">figure 3</xref><italic>a</italic>). HD patients suffer from motor abnormalities and non-motor symptoms, including cognitive deficits, psychiatric symptoms, sleep disturbance, irritability, anxiety, depression and an increased incidence of seizures [<xref ref-type="bibr" rid="RSOB180165C74">74</xref>,<xref ref-type="bibr" rid="RSOB180165C77">77</xref>,<xref ref-type="bibr" rid="RSOB180165C116">116</xref>,<xref ref-type="bibr" rid="RSOB180165C117">117</xref>]. Seizures are a well-established part of juvenile HD but no more prevalent in adult-onset HD than in the general population [<xref ref-type="bibr" rid="RSOB180165C73">73</xref>,<xref ref-type="bibr" rid="RSOB180165C74">74</xref>,<xref ref-type="bibr" rid="RSOB180165C118">118</xref>]. Several pharmacological compounds can enhance inhibitory GABAergic neurotransmission by targeting GABA<sub>A</sub>R and thereby producing sedative, anxiolytic, anticonvulsant and muscle-relaxant effects. A recent study demonstrated that zolpidem, a GABA<sub>A</sub>R modulator that enhances GABA inhibition mainly via the α<sub>1</sub>-containing GABA<sub>A</sub> receptors, corrected sleep disturbance and electroencephalographic abnormalities in symptomatic HD mice (R6/2) [<xref ref-type="bibr" rid="RSOB180165C119">119</xref>]. Alprazolam, a benzodiazepine-activating GABA receptor, reversed the dysregulated circadian rhythms and improved cognitive performance of HD mice (R6/2) [<xref ref-type="bibr" rid="RSOB180165C120">120</xref>]. In addition, progesterone, a positive modulator of GABA<sub>A</sub>R, significantly reversed the behavioural impairment in a 3-nitropropionic acid (3-NP)-induced HD rat model [<xref ref-type="bibr" rid="RSOB180165C121">121</xref>]. Apart from modulating the activity of the GABAergic system by interfering directly with the receptor, pharmacological agents can also interfere with synaptic GABA concentrations. Tiagabine, a drug that specifically blocks the GABA transporter (GAT1) to increase synaptic GABA level, was found to improve motor performance and extend survival in N171-82Q and R6/2 mice [<xref ref-type="bibr" rid="RSOB180165C122">122</xref>]. It is also worth evaluating whether vigabatrin, a GABA-T inhibitor that blocks GABA catabolism in neurons and astrocytes [<xref ref-type="bibr" rid="RSOB180165C123">123</xref>], plays a role in the compromised astrocytic glutamate–GABA–glutamine cycling [<xref ref-type="bibr" rid="RSOB180165C56">56</xref>]. Interestingly, taurine exerted GABA<sub>A</sub> agonistic and antioxidant activities in a 3-NP HD model and improved locomotor deficits and increased GABA levels [<xref ref-type="bibr" rid="RSOB180165C124">124</xref>].
<fig id="RSOB180165F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Strategy to target (<italic>a</italic>) GABA<sub>A</sub>R and (<italic>b</italic>) cation–chloride cotransporters as potential therapeutic avenues. (<italic>a</italic>) The GABAergic system is influenced directly by agents that (1) target synaptic GABA<sub>A</sub>R, (2) increase tonic GABA current or interfere with synaptic GABA concentrations via a reduction of GABA reuptake (3), and (4) block GABA metabolism. (<italic>b</italic>) GABA<sub>A</sub>R-mediated signalling in HD neurons is depolarizing due to the high intracellular chloride concentration caused by high NKCC1 expression and low KCC2 expression. Rescuing the function of cation–chloride cotransporters can occur via (1) inhibition of NKCC1 activity using bumetanide, (2, 3) increase in KCC2 function using a KCC2 activator or CKB enhancer, and (4) inhibitors of WNK/SPAK kinases.</p></caption><graphic xlink:href="rsob-8-180165-g3"></graphic></fig></p>
<p>However, several early studies failed to provide the expected benefits of GABA analogues in slowing disease progression in HD patients [<xref ref-type="bibr" rid="RSOB180165C125">125</xref>–<xref ref-type="bibr" rid="RSOB180165C127">127</xref>]. For example, gaboxadol, an agonist for the extrasynaptic δ-containing GABA<sub>A</sub> receptor, failed to improve the decline in cognitive and motor functions of five HD patients during a short two-week trial, but it caused side effects at the maximal dose [<xref ref-type="bibr" rid="RSOB180165C125">125</xref>]. Interestingly, although treatment with muscimol (a potent agonist of GABA receptors) did not improve motor or cognitive deficits in 10 HD patients, it did ameliorate chorea in the most severely hyperkinetic patient [<xref ref-type="bibr" rid="RSOB180165C126">126</xref>]. The therapeutic failure of GABA stimulation in early clinical trials does not argue against the importance of GABAergic deficits in HD pathogenesis. The alteration of GABAergic circuits plays a primary role or is a compensatory response to excitotoxicity, and it may contribute to HD by disrupting the balance between the excitation and inhibition systems and the overall functions of neuronal circuits. Because the subunits of the GABA<sub>A</sub> receptor are brain region- or neuron subtype-specific, the choice of drugs may have distinct effects on the brain region or neuronal population targeted [<xref ref-type="bibr" rid="RSOB180165C128">128</xref>–<xref ref-type="bibr" rid="RSOB180165C130">130</xref>]. For example, the expression of GABA<sub>A</sub>R subunits is differentially altered in MSNs and other striatal interneurons in HD [<xref ref-type="bibr" rid="RSOB180165C54">54</xref>,<xref ref-type="bibr" rid="RSOB180165C60">60</xref>]. The early involvement of D2-expressing MSNs can cause chorea [<xref ref-type="bibr" rid="RSOB180165C131">131</xref>], while dysfunctional PV-expressing interneurons can cause dystonia in HD patients [<xref ref-type="bibr" rid="RSOB180165C132">132</xref>]. Specific alteration in neuronal populations and receptor-subtypes during HD progression needs to be taken into consideration when treating the dysfunction of GABAergic circuitry. Notably, striatal tonic inhibition mediated by the δ-containing GABA<sub>A</sub>Rs may have neuroprotective effects against excitotoxicity in the adult striatum [<xref ref-type="bibr" rid="RSOB180165C63">63</xref>]. Because the reductions in δ-containing GABA<sub>A</sub>Rs and tonic GABA currents in D2-expressing MSNs have been observed in early HD [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>,<xref ref-type="bibr" rid="RSOB180165C39">39</xref>,<xref ref-type="bibr" rid="RSOB180165C40">40</xref>,<xref ref-type="bibr" rid="RSOB180165C54">54</xref>,<xref ref-type="bibr" rid="RSOB180165C61">61</xref>], it would be of great interest to evaluate the effects of several available compounds, such as alphaxalone and ganaxolone [<xref ref-type="bibr" rid="RSOB180165C133">133</xref>], that target δ-containing GABA<sub>A</sub>Rs, in animal models of HD.</p>
</sec>
<sec id="s5b">
<label>5.2.</label>
<title>Modulation of chloride homeostasis via cation–chloride cotransporters</title>
<p>Emerging evidence suggests that chloride homeostasis is a therapeutic target for HD. Pharmacological agents that target cation–chloride cotransporters (i.e. NKCC1 or KCC2) therefore might be used to treat HD (<xref ref-type="fig" rid="RSOB180165F3">figure 3</xref><italic>b</italic>). Of note, dysregulation of cation–chloride cotransporters and GABA polarity was associated with several neuropsychiatric disorders [<xref ref-type="bibr" rid="RSOB180165C70">70</xref>,<xref ref-type="bibr" rid="RSOB180165C134">134</xref>–<xref ref-type="bibr" rid="RSOB180165C139">139</xref>] (reviewed in [<xref ref-type="bibr" rid="RSOB180165C27">27</xref>,<xref ref-type="bibr" rid="RSOB180165C140">140</xref>]). Such abnormal excitatory GABA<sub>A</sub> receptor neurotransmission can be rescued by bumetanide, an NKCC1 inhibitor that decreases intracellular chloride concentration. Bumetanide is an FDA-approved diuretic agent that has been used in the clinic. It attenuates many neurological and psychiatric disorders in preclinical studies and some clinical trials for traumatic brain injury, seizure, chronic pain, cerebral infarction, Down syndrome, schizophrenia, fragile X syndrome and autism (reviewed in [<xref ref-type="bibr" rid="RSOB180165C141">141</xref>]). Daily intraperitoneal injections of bumetanide also restored the impaired motor function of HD mice (R6/2, Y-T Hsu, Y-G Chang, Y-C Li, K-Y Wang, H-M Chen, D-J Lee, C-H Tsai, C-C Lien, Y Chern 2018, personal communication). The effect of bumetanide is likely to be mediated by NKCC1 because genetic ablation of NKCC1 in the striatum also rescued the motor deficits in R6/2 mice (Y-T Hsu, Y-G Chang, Y-C Li, K-Y Wang, H-M Chen, D-J Lee, C-H Tsai, C-C Lien, Y Chern 2018, personal communication). This study uncovered a previously unrecognized depolarizing or excitatory action of GABA in the aberrant motor control in HD. In addition, chronic treatment with bumetanide also improved the impaired memory in R6/2 mice [<xref ref-type="bibr" rid="RSOB180165C69">69</xref>], supporting the importance of NKCC1 in HD pathogenesis. Owing to the poor ability of bumetanide to pass through the blood–brain barrier, further optimization of bumetanide and other NKCC1 inhibitors is warranted [<xref ref-type="bibr" rid="RSOB180165C142">142</xref>,<xref ref-type="bibr" rid="RSOB180165C143">143</xref>].</p>
<p>Disruption of KCC2 function is detrimental to inhibitory transmission and agents to activate KCC2 function would be beneficial in HD. However, no agonist of KCC2 has been described until very recently [<xref ref-type="bibr" rid="RSOB180165C144">144</xref>,<xref ref-type="bibr" rid="RSOB180165C145">145</xref>]. A new KCC2 agonist (CLP290) has been shown to facilitate functional recovery after spinal cord injury [<xref ref-type="bibr" rid="RSOB180165C145">145</xref>]. It would be of great interest to evaluate the effect of KCC2 agonists on HD progression. Another KCC2 activator, CLP257, was found to increase the cell surface expression of KCC2 in a rat model of neuropathic pain [<xref ref-type="bibr" rid="RSOB180165C146">146</xref>]. Post-translational modification of KCC2 by kinases may modulate the function of KCC2. The WNK/SPAK kinase complex, composed of WNK (with no lysine) and SPAK (SPS1-related proline/alanine-rich kinase), is known to phosphorylate and stimulate NKCC1 or inhibit KCC2 [<xref ref-type="bibr" rid="RSOB180165C147">147</xref>]. Thus, compounds that inhibit WNK/SPAK kinases will result in KCC2 activation and NKCC1 inhibition. Some compounds have been noted as potential inhibitors of WNK/SPAK kinases and need to be further tested for their effects on cation–chloride cotransporters [<xref ref-type="bibr" rid="RSOB180165C148">148</xref>–<xref ref-type="bibr" rid="RSOB180165C150">150</xref>]. An alternative mechanism to activate KCC2 is manipulation of its interacting proteins (e.g. CKB [<xref ref-type="bibr" rid="RSOB180165C65">65</xref>,<xref ref-type="bibr" rid="RSOB180165C66">66</xref>]). Because CKB could activate the function of KCC2 [<xref ref-type="bibr" rid="RSOB180165C65">65</xref>,<xref ref-type="bibr" rid="RSOB180165C66">66</xref>], CKB enhancers may increase the function of KCC2. In HD, reduced expression and activity of CKB is associated with motor deficits and hearing impairment [<xref ref-type="bibr" rid="RSOB180165C68">68</xref>,<xref ref-type="bibr" rid="RSOB180165C88">88</xref>]. Enhancing CKB activity by creatine supplements ameliorated the motor deficits and hearing impairment of HD mice. It is worthwhile to further investigate the interaction of KCC2 and CKB in GABAergic neurotransmission and motor deficits in HD.</p>
<p>The depolarizing GABA action with altered expression levels of NKCC1 or KCC2 is associated with neuroinflammation in HD brains [<xref ref-type="bibr" rid="RSOB180165C32">32</xref>,<xref ref-type="bibr" rid="RSOB180165C69">69</xref>]. Blockade of TNF-α using Xpro1595 (a dominant negative inhibitor of soluble TNF-α) [<xref ref-type="bibr" rid="RSOB180165C151">151</xref>] <italic>in vivo</italic> led to significant beneficial effects on disease progression in HD mice [<xref ref-type="bibr" rid="RSOB180165C152">152</xref>] and reduced the expression of NKCC1 (Y-T Hsu, Y-G Chang, Y-C Li, K-Y Wang, H-M Chen, D-J Lee, C-H Tsai, C-C Lien, Y Chern 2018, personal communication). It would be of great interest to test the effect of other anti-inflammatory agents [<xref ref-type="bibr" rid="RSOB180165C153">153</xref>] on the function and expression of NKCC1 and GABAergic inhibition. Neuroinflammation is implicated in most neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease [<xref ref-type="bibr" rid="RSOB180165C154">154</xref>,<xref ref-type="bibr" rid="RSOB180165C155">155</xref>], and the interaction of cation–chloride cotransporters and neuroinflammation in GABAergic neurotransmission may also play a critical role in other neurodegenerative diseases.</p>
</sec>
</sec>
<sec id="s6">
<label>6.</label>
<title>Concluding remark</title>
<p>Although tremendous understanding of HD pathogenesis has been achieved in recent years, there is still no effective therapy to prevent or halt disease progression. A global characterization of excitatory and inhibitory neurotransmission in HD brains is critical, and it may provide the molecular insight needed to develop novel therapeutic treatments for HD. In this review, we focused on alterations of GABAergic inhibitory systems, which precede the appearance of overt symptoms in HD. Emerging evidence has revealed alterations in various components of the GABA<sub>A</sub>ergic system, including GABA levels, GAD activity, phasic or tonic GABA currents, the distribution and composition of GABA<sub>A</sub>R and cation–chloride cotransporters. Some of these alterations are caused by mutant HTT, neuroinflammation, excitotoxicity and other factors that remain elusive. Altered GABAergic signalling may lead to an imbalance between excitation and inhibition, which underlies the motor and cognitive impairments in HD. In summary, GABA<sub>A</sub>R and cation–chloride cotransporters are important therapeutic targets for HD.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="d35e182">
<caption>
<title>Reviewer comments</title>
</caption>
<media mime-subtype="pdf" mimetype="application" xlink:href="rsob180165_review_history.pdf"></media>
</supplementary-material>
</sec>
</body>
<back>
<sec id="s7">
<title>Data accessibility</title>
<p>This article has no additional data.</p>
</sec>
<sec id="s8">
<title>Authors' contributions</title>
<p>Y.T.H., Y.G.C. and Y.C. drafted and revised the manuscript. All authors gave final approval before submission.</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Competing interests</title>
<p>We declare we have no competing interests.</p>
</sec>
<sec id="s10">
<title>Funding</title>
<p>This study was supported by a grant from China Medical University Hospital (CRS-106-060) to Y.T.H.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="RSOB180165C1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>ME</given-names></name><etal>et al.</etal></person-group>
<year>1993</year>
<article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group</article-title>. <source/>Cell
<volume>72</volume>, <fpage>971</fpage>–<lpage>983</lpage>. (<pub-id pub-id-type="doi">10.1016/0092-8674(93)90585-E</pub-id>)<pub-id pub-id-type="pmid">8458085</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>FO</given-names></name></person-group>
<year>2007</year>
<article-title>Huntington's disease</article-title>. <source/>Lancet
<volume>369</volume>, <fpage>218</fpage>–<lpage>228</lpage>. (<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60111-1</pub-id>)<pub-id pub-id-type="pmid">17240289</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Identification of genetic factors that modify clinical onset of Huntington's disease</article-title>. <source/>Cell
<volume>162</volume>, <fpage>516</fpage>–<lpage>526</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2015.07.003</pub-id>)<pub-id pub-id-type="pmid">26232222</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>DJH</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study</article-title>. <source/>The Lancet Neurol.
<volume>16</volume>, <fpage>701</fpage>–<lpage>711</lpage>. (<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30161-8</pub-id>)<pub-id pub-id-type="pmid">28642124</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cepeda</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Andre</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>MS</given-names></name></person-group>
<year>2007</year>
<article-title>The corticostriatal pathway in Huntington's disease</article-title>. <source/>Prog. Neurobiol.
<volume>81</volume>, <fpage>253</fpage>–<lpage>271</lpage>. (<pub-id pub-id-type="doi">10.1016/j.pneurobio.2006.11.001</pub-id>)<pub-id pub-id-type="pmid">17169479</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vonsattel</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Stevens</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Ferrante</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>EP</given-names><suffix>Jr</suffix></name></person-group>
<year>1985</year>
<article-title>Neuropathological classification of Huntington's disease</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>44</volume>, <fpage>559</fpage>–<lpage>577</lpage>. (<pub-id pub-id-type="doi">10.1097/00005072-198511000-00003</pub-id>)<pub-id pub-id-type="pmid">2932539</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Kowall</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Beal</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>EP</given-names><suffix>Jr</suffix></name></person-group>
<year>1987</year>
<article-title>Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>46</volume>, <fpage>12</fpage>–<lpage>27</lpage>. (<pub-id pub-id-type="doi">10.1097/00005072-198701000-00002</pub-id>)<pub-id pub-id-type="pmid">2947977</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graybiel</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Aosaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Flaherty</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Kimura</surname><given-names>M</given-names></name></person-group>
<year>1994</year>
<article-title>The basal ganglia and adaptive motor control</article-title>. <source/>Science
<volume>265</volume>, <fpage>1826</fpage>–<lpage>1831</lpage>. (<pub-id pub-id-type="doi">10.1126/science.8091209</pub-id>)<pub-id pub-id-type="pmid">8091209</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Augood</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Emson</surname><given-names>PC</given-names></name></person-group>
<year>1997</year>
<article-title>Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease</article-title>. <source/>Ann. Neurol.
<volume>42</volume>, <fpage>215</fpage>–<lpage>221</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.410420213</pub-id>)<pub-id pub-id-type="pmid">9266732</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dragunow</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name></person-group>
<year>2000</year>
<article-title>The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease</article-title>. <source/>Neuroscience
<volume>97</volume>, <fpage>505</fpage>–<lpage>519</lpage>. (<pub-id pub-id-type="doi">10.1016/S0306-4522(00)00008-7</pub-id>)<pub-id pub-id-type="pmid">10828533</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vonsattel</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>DiFiglia</surname><given-names>M</given-names></name></person-group>
<year>1998</year>
<article-title>Huntington disease</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>57</volume>, <fpage>369</fpage>–<lpage>384</lpage>. (<pub-id pub-id-type="doi">10.1097/00005072-199805000-00001</pub-id>)<pub-id pub-id-type="pmid">9596408</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Raymond</surname><given-names>LA</given-names></name></person-group>
<year>2007</year>
<article-title>N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease</article-title>. <source/>Prog. Neurobiol.
<volume>81</volume>, <fpage>272</fpage>–<lpage>293</lpage>. (<pub-id pub-id-type="doi">10.1016/j.pneurobio.2006.11.003</pub-id>)<pub-id pub-id-type="pmid">17188796</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milnerwood</surname><given-names>AJ</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice</article-title>. <source/>Neurobiol. Dis.
<volume>48</volume>, <fpage>40</fpage>–<lpage>51</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2012.05.013</pub-id>)<pub-id pub-id-type="pmid">22668780</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tessler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Emson</surname><given-names>PC</given-names></name></person-group>
<year>2008</year>
<article-title>Glutamate uptake is reduced in prefrontal cortex in Huntington's disease</article-title>. <source/>Neurochem. Res.
<volume>33</volume>, <fpage>232</fpage>–<lpage>237</lpage>. (<pub-id pub-id-type="doi">10.1007/s11064-007-9463-1</pub-id>)<pub-id pub-id-type="pmid">17726644</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owens</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Kriegstein</surname><given-names>AR</given-names></name></person-group>
<year>2002</year>
<article-title>Is there more to GABA than synaptic inhibition?</article-title>
<source/>Nat. Rev. Neurosci.
<volume>3</volume>, <fpage>715</fpage>–<lpage>727</lpage>. (<pub-id pub-id-type="doi">10.1038/nrn919</pub-id>)<pub-id pub-id-type="pmid">12209120</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>BE</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition</article-title>. <source/>J. Physiol.
<volume>592</volume>, <fpage>4951</fpage>–<lpage>4968</lpage>. (<pub-id pub-id-type="doi">10.1113/jphysiol.2014.278754</pub-id>)<pub-id pub-id-type="pmid">25239459</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Berglund</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Oh</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Augustine</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>CJ</given-names></name></person-group>
<year>2010</year>
<article-title>Channel-mediated tonic GABA release from glia</article-title>. <source/>Science
<volume>330</volume>, <fpage>790</fpage>–<lpage>796</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1184334</pub-id>)<pub-id pub-id-type="pmid">20929730</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Minelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Melone</surname><given-names>M</given-names></name></person-group>
<year>2004</year>
<article-title>GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications</article-title>. <source/>Brain Res. Rev.
<volume>45</volume>, <fpage>196</fpage>–<lpage>212</lpage>. (<pub-id pub-id-type="doi">10.1016/j.brainresrev.2004.03.003</pub-id>)<pub-id pub-id-type="pmid">15210304</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>DeBiasi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Brecha</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Zuccarello</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Conti</surname><given-names>F</given-names></name></person-group>
<year>1996</year>
<article-title>GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex</article-title>. <source/>J. Neurosci.
<volume>16</volume>, <fpage>6255</fpage>–<lpage>6264</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-19-06255.1996</pub-id>)<pub-id pub-id-type="pmid">8815906</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bak</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Schousboe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Waagepetersen</surname><given-names>HS</given-names></name></person-group>
<year>2006</year>
<article-title>The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer</article-title>. <source/>J. Neurochem.
<volume>98</volume>, <fpage>641</fpage>–<lpage>653</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03913.x</pub-id>)<pub-id pub-id-type="pmid">16787421</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Sieghart</surname><given-names>W</given-names></name></person-group>
<year>2008</year>
<article-title>International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update</article-title>. <source/>Pharmacol. Rev.
<volume>60</volume>, <fpage>243</fpage>–<lpage>260</lpage>. (<pub-id pub-id-type="doi">10.1124/pr.108.00505</pub-id>)<pub-id pub-id-type="pmid">18790874</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Sieghart</surname><given-names>W</given-names></name></person-group>
<year>2009</year>
<article-title>GABA A receptors: subtypes provide diversity of function and pharmacology</article-title>. <source/>Neuropharmacology
<volume>56</volume>, <fpage>141</fpage>–<lpage>148</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.07.045</pub-id>)<pub-id pub-id-type="pmid">18760291</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brickley</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Mody</surname><given-names>I</given-names></name></person-group>
<year>2012</year>
<article-title>Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease</article-title>. <source/>Neuron
<volume>73</volume>, <fpage>23</fpage>–<lpage>34</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2011.12.012</pub-id>)<pub-id pub-id-type="pmid">22243744</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrant</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nusser</surname><given-names>Z</given-names></name></person-group>
<year>2005</year>
<article-title>Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors</article-title>. <source/>Nat. Rev. Neurosci.
<volume>6</volume>, <fpage>215</fpage>–<lpage>229</lpage>. (<pub-id pub-id-type="doi">10.1038/nrn1625</pub-id>)<pub-id pub-id-type="pmid">15738957</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emson</surname><given-names>PC</given-names></name></person-group>
<year>2007</year>
<article-title>GABA(B) receptors: structure and function</article-title>. <source/>Prog. Brain Res.
<volume>160</volume>, <fpage>43</fpage>–<lpage>57</lpage>. (<pub-id pub-id-type="doi">10.1016/S0079-6123(06)60004-6</pub-id>)<pub-id pub-id-type="pmid">17499108</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaupmann</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<year>1997</year>
<article-title>Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors</article-title>. <source/>Nature
<volume>386</volume>, <fpage>239</fpage>–<lpage>246</lpage>. (<pub-id pub-id-type="doi">10.1038/386239a0</pub-id>)<pub-id pub-id-type="pmid">9069281</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaila</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Puskarjov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Voipio</surname><given-names>J</given-names></name></person-group>
<year>2014</year>
<article-title>Cation-chloride cotransporters in neuronal development, plasticity and disease</article-title>. <source/>Nat. Rev. Neurosci.
<volume>15</volume>, <fpage>637</fpage>–<lpage>654</lpage>. (<pub-id pub-id-type="doi">10.1038/nrn3819</pub-id>)<pub-id pub-id-type="pmid">25234263</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaesse</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Airaksinen</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kaila</surname><given-names>K</given-names></name></person-group>
<year>2009</year>
<article-title>Cation-chloride cotransporters and neuronal function</article-title>. <source/>Neuron
<volume>61</volume>, <fpage>820</fpage>–<lpage>838</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.003</pub-id>)<pub-id pub-id-type="pmid">19323993</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpire</surname><given-names>E</given-names></name></person-group>
<year>2000</year>
<article-title>Cation-chloride cotransporters in neuronal communication</article-title>. <source/>News Physiol. Sci.
<volume>15</volume>, <fpage>309</fpage>–<lpage>312</lpage>. (<pub-id pub-id-type="doi">10.1152/physiologyonline.2000.15.6.309</pub-id>)<pub-id pub-id-type="pmid">11390932</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gourfinkel-An</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Parain</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hartmann</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mangiarini</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Brice</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bates</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hirsch</surname><given-names>EC</given-names></name></person-group>
<year>2003</year>
<article-title>Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice</article-title>. <source/>J. Neurochem.
<volume>86</volume>, <fpage>1369</fpage>–<lpage>1378</lpage>. (<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01916.x</pub-id>)<pub-id pub-id-type="pmid">12950446</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunig</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leenders</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Sanchez-Pernaute</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Antonini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vontobel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Verhagen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gunther</surname><given-names>I</given-names></name></person-group>
<year>2000</year>
<article-title>Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography</article-title>. <source/>Ann. Neurol.
<volume>47</volume>, <fpage>644</fpage>–<lpage>648</lpage>. (<pub-id pub-id-type="doi">10.1002/1531-8249(200005)47:5%3C644::AID-ANA13%3E3.0.CO;2-C</pub-id>)<pub-id pub-id-type="pmid">10805336</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>YG</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Siew</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Chern</surname><given-names>Y</given-names></name></person-group>
<year>2017</year>
<article-title>Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease</article-title>. <source/>Movement Disord.
<volume>32</volume>, <fpage>1600</fpage>–<lpage>1609</lpage>. (<pub-id pub-id-type="doi">10.1002/mds.27107</pub-id>)<pub-id pub-id-type="pmid">28782830</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chazalon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bestaven</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Leste-Lasserre</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Baufreton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cazalets</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Garret</surname><given-names>M</given-names></name></person-group>
<year>2016</year>
<article-title>Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease</article-title>. <source/>Neuroscience
<volume>329</volume>, <fpage>363</fpage>–<lpage>379</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.05.027</pub-id>)<pub-id pub-id-type="pmid">27217211</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuen</surname><given-names>EY</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name></person-group>
<year>2012</year>
<article-title>Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease</article-title>. <source/>Neurobiol. Dis.
<volume>46</volume>, <fpage>497</fpage>–<lpage>502</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2012.02.015</pub-id>)<pub-id pub-id-type="pmid">22402331</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice</article-title>. <source/>Neuron
<volume>46</volume>, <fpage>433</fpage>–<lpage>444</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2005.03.025</pub-id>)<pub-id pub-id-type="pmid">15882643</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ade</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Janssen</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ortinski</surname><given-names>PI</given-names></name>, <name name-style="western"><surname>Vicini</surname><given-names>S</given-names></name></person-group>
<year>2008</year>
<article-title>Differential tonic GABA conductances in striatal medium spiny neurons</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>1185</fpage>–<lpage>1197</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3908-07.2008</pub-id>)<pub-id pub-id-type="pmid">18234896</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Andre</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Uzgil</surname><given-names>BO</given-names></name>, <name name-style="western"><surname>Gee</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>YE</given-names></name>, <name name-style="western"><surname>Cepeda</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>MS</given-names></name></person-group>
<year>2009</year>
<article-title>Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>10 371</fpage>–<lpage>10 386</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1592-09.2009</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Cepeda</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>MS</given-names></name></person-group>
<year>2010</year>
<article-title>Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease</article-title>. <source/>ASN Neuro
<volume>2</volume>, <fpage>e00036</fpage> (<pub-id pub-id-type="doi">10.1042/AN20100007</pub-id>)<pub-id pub-id-type="pmid">20585470</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cepeda</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>7393</fpage>–<lpage>7406</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2137-12.2013</pub-id>)<pub-id pub-id-type="pmid">23616545</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wojtowicz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Dvorzhak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Semtner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grantyn</surname><given-names>R</given-names></name></person-group>
<year>2013</year>
<article-title>Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3</article-title>. <source/>Front. Neural Circ.
<volume>7</volume>, <fpage>188</fpage> (<pub-id pub-id-type="doi">10.3389/fncir.2013.00188</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangiarini</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>1996</year>
<article-title>Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice</article-title>. <source/>Cell
<volume>87</volume>, <fpage>493</fpage>–<lpage>506</lpage>. (<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81369-0</pub-id>)<pub-id pub-id-type="pmid">8898202</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naver</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Stub</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Moller</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fenger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Hasholt</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sorensen</surname><given-names>SA</given-names></name></person-group>
<year>2003</year>
<article-title>Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse</article-title>. <source/>Neuroscience
<volume>122</volume>, <fpage>1049</fpage>–<lpage>1057</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuroscience.2003.08.053</pub-id>)<pub-id pub-id-type="pmid">14643771</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schilling</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<year>1999</year>
<article-title>Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin</article-title>. <source/>Hum. Mol. Genet.
<volume>8</volume>, <fpage>397</fpage>–<lpage>407</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/8.3.397</pub-id>)<pub-id pub-id-type="pmid">9949199</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slow</surname><given-names>EJ</given-names></name><etal>et al.</etal></person-group>
<year>2003</year>
<article-title>Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease</article-title>. <source/>Hum. Mol. Genet.
<volume>12</volume>, <fpage>1555</fpage>–<lpage>1567</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/ddg169</pub-id>)<pub-id pub-id-type="pmid">12812983</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>6182</fpage>–<lpage>6195</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0857-08.2008</pub-id>)<pub-id pub-id-type="pmid">18550760</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menalled</surname><given-names>LB</given-names></name></person-group>
<year>2005</year>
<article-title>Knock-in mouse models of Huntington's disease</article-title>. <source/>NeuroRx
<volume>2</volume>, <fpage>465</fpage>–<lpage>470</lpage>. (<pub-id pub-id-type="doi">10.1602/neurorx.2.3.465</pub-id>)<pub-id pub-id-type="pmid">16389309</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garret</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chazalon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Baufreton</surname><given-names>J</given-names></name></person-group>
<year>2018</year>
<article-title>Alteration of GABAergic neurotransmission in Huntington's disease</article-title>. <source/>CNS Neurosci. Ther.
<volume>24</volume>, <fpage>292</fpage>–<lpage>300</lpage>. (<pub-id pub-id-type="doi">10.1111/cns.12826</pub-id>)<pub-id pub-id-type="pmid">29464851</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spokes</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Garrett</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Iversen</surname><given-names>LL</given-names></name></person-group>
<year>1980</year>
<article-title>Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects</article-title>. <source/>J. Neurol. Sci.
<volume>48</volume>, <fpage>303</fpage>–<lpage>313</lpage>. (<pub-id pub-id-type="doi">10.1016/0022-510X(80)90103-3</pub-id>)<pub-id pub-id-type="pmid">6449563</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kloster</surname><given-names>M</given-names></name></person-group>
<year>1973</year>
<article-title>Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain</article-title>. <source/>N. Engl. J. Med.
<volume>288</volume>, <fpage>337</fpage>–<lpage>342</lpage>. (<pub-id pub-id-type="doi">10.1056/NEJM197302152880703</pub-id>)<pub-id pub-id-type="pmid">4345566</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Pearson</surname><given-names>SJ</given-names></name></person-group>
<year>1990</year>
<article-title>Brain GABA levels in asymptomatic Huntington's disease</article-title>. <source/>N. Engl. J. Med.
<volume>323</volume>, <fpage>682</fpage> (<pub-id pub-id-type="doi">10.1056/NEJM199009063231014</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Pearson</surname><given-names>SJ</given-names></name></person-group>
<year>1987</year>
<article-title>Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain</article-title>. <source/>Neurosci. Lett.
<volume>78</volume>, <fpage>233</fpage>–<lpage>238</lpage>. (<pub-id pub-id-type="doi">10.1016/0304-3940(87)90639-2</pub-id>)<pub-id pub-id-type="pmid">2442679</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spokes</surname><given-names>EG</given-names></name></person-group>
<year>1980</year>
<article-title>Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue</article-title>. <source/>Brain
<volume>103</volume>, <fpage>179</fpage>–<lpage>210</lpage>. (<pub-id pub-id-type="doi">10.1093/brain/103.1.179</pub-id>)<pub-id pub-id-type="pmid">6102490</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urquhart</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>J</given-names></name></person-group>
<year>1975</year>
<article-title>GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects</article-title>. <source/>J. Neurochem.
<volume>24</volume>, <fpage>1071</fpage>–<lpage>1075</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1471-4159.1975.tb03679.x</pub-id>)<pub-id pub-id-type="pmid">124764</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tertrais</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Courtand</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leste-Lasserre</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cardoit</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Masmejean</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Halgand</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Garret</surname><given-names>M</given-names></name></person-group>
<year>2017</year>
<article-title>Differential alteration in expression of striatal GABAAR subunits in mouse models of Huntington's disease</article-title>. <source/>Front. Mol. Neurosci.
<volume>10</volume>, <fpage>198</fpage> (<pub-id pub-id-type="doi">10.3389/fnmol.2017.00198</pub-id>)<pub-id pub-id-type="pmid">28676743</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>RG</given-names></name></person-group>
<year>2017</year>
<article-title>Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice</article-title>. <source/>Nat. Neurosci.
<volume>20</volume>, <fpage>648</fpage>–<lpage>660</lpage>. (<pub-id pub-id-type="doi">10.1038/nn.4532</pub-id>)<pub-id pub-id-type="pmid">28319609</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skotte</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Santos</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Aldana</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Willert</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Norremolle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Waagepetersen</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>ML</given-names></name></person-group>
<year>2018</year>
<article-title>Integrative characterization of the R6/2 mouse model of Huntington's disease reveals dysfunctional astrocyte metabolism</article-title>. <source/>Cell Rep.
<volume>23</volume>, <fpage>2211</fpage>–<lpage>2224</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.052</pub-id>)<pub-id pub-id-type="pmid">29768217</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisine</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Wastek</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Speth</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Yamamura</surname><given-names>HI</given-names></name></person-group>
<year>1979</year>
<article-title>Alterations in the benzodiazepine receptor of Huntington's diseased human brain</article-title>. <source/>Brain Res.
<volume>165</volume>, <fpage>183</fpage>–<lpage>187</lpage>. (<pub-id pub-id-type="doi">10.1016/0006-8993(79)90060-X</pub-id>)<pub-id pub-id-type="pmid">34467</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>FO</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Penney</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Dovorini-Zis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shoulson</surname><given-names>I</given-names></name></person-group>
<year>1984</year>
<article-title>Benzodiazepine and GABA receptors in early Huntington's disease</article-title>. <source/>Neurology
<volume>34</volume>, <fpage>1237</fpage>–<lpage>1240</lpage>. (<pub-id pub-id-type="doi">10.1212/WNL.34.9.1237</pub-id>)<pub-id pub-id-type="pmid">6087209</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holthoff</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Frey</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Penney</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Markel</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Kuhl</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>AB</given-names></name></person-group>
<year>1993</year>
<article-title>Positron emission tomography measures of benzodiazepine receptors in Huntington's disease</article-title>. <source/>Ann. Neurol.
<volume>34</volume>, <fpage>76</fpage>–<lpage>81</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.410340114</pub-id>)<pub-id pub-id-type="pmid">8390806</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldvogel</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name></person-group>
<year>2015</year>
<article-title>The diversity of GABA(A) receptor subunit distribution in the normal and Huntington's disease human brain</article-title>. <source/>Adv. Pharmacol.
<volume>73</volume>, <fpage>223</fpage>–<lpage>264</lpage>. (<pub-id pub-id-type="doi">10.1016/bs.apha.2014.11.010</pub-id>)<pub-id pub-id-type="pmid">25637443</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosas-Arellano</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tejeda-Guzman</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lorca-Ponce</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Palma-Tirado</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mantellero</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Rojas</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Missirlis</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Castro</surname><given-names>MA</given-names></name></person-group>
<year>2018</year>
<article-title>Huntington's disease leads to decrease of GABA-A tonic subunits in the D2 neostriatal pathway and their relocalization into the synaptic cleft</article-title>. <source/>Neurobiol. Dis.
<volume>110</volume>, <fpage>142</fpage>–<lpage>153</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2017.11.010</pub-id>)<pub-id pub-id-type="pmid">29196217</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spampanato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>XW</given-names></name>, <name name-style="western"><surname>Mody</surname><given-names>I</given-names></name></person-group>
<year>2008</year>
<article-title>Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease</article-title>. <source/>Neuroscience
<volume>157</volume>, <fpage>606</fpage>–<lpage>620</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.09.020</pub-id>)<pub-id pub-id-type="pmid">18854207</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santhakumar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Mody</surname><given-names>I</given-names></name></person-group>
<year>2010</year>
<article-title>Developmental regulation and neuroprotective effects of striatal tonic GABAA currents</article-title>. <source/>Neuroscience
<volume>167</volume>, <fpage>644</fpage>–<lpage>655</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.02.048</pub-id>)<pub-id pub-id-type="pmid">20206233</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philpott</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Cummins</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Churchyard</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Georgiou-Karistianis</surname><given-names>N</given-names></name></person-group>
<year>2016</year>
<article-title>Cortical inhibitory deficits in premanifest and early Huntington's disease</article-title>. <source/>Behav. Brain Res.
<volume>296</volume>, <fpage>311</fpage>–<lpage>317</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbr.2015.09.030</pub-id>)<pub-id pub-id-type="pmid">26416671</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fukuda</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>Interaction of neuron-specific K<sup>+</sup>-Cl<sup>−</sup> cotransporter, KCC2, with brain-type creatine kinase</article-title>. <source/>FEBS Lett.
<volume>564</volume>, <fpage>131</fpage>–<lpage>135</lpage>. (<pub-id pub-id-type="doi">10.1016/S0014-5793(04)00328-X</pub-id>)<pub-id pub-id-type="pmid">15094054</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ueno</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fukuda</surname><given-names>A</given-names></name></person-group>
<year>2006</year>
<article-title>Brain-type creatine kinase activates neuron-specific K<sup>+</sup>-Cl<sup>−</sup> co-transporter KCC2</article-title>. <source/>J. Neurochem.
<volume>96</volume>, <fpage>598</fpage>–<lpage>608</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03560.x</pub-id>)<pub-id pub-id-type="pmid">16336223</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Hennessey</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Starkova</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Beal</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Starkov</surname><given-names>AA</given-names></name></person-group>
<year>2011</year>
<article-title>Impaired brain creatine kinase activity in Huntington's disease</article-title>. <source/>Neurodegener. Dis.
<volume>8</volume>, <fpage>194</fpage>–<lpage>201</lpage>. (<pub-id pub-id-type="doi">10.1159/000321681</pub-id>)<pub-id pub-id-type="pmid">21124007</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Chern</surname><given-names>Y</given-names></name></person-group>
<year>2013</year>
<article-title>Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease</article-title>. <source/>Biochim. Biophys. Acta
<volume>1832</volume>, <fpage>742</fpage>–<lpage>753</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbadis.2013.02.006</pub-id>)<pub-id pub-id-type="pmid">23416527</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dargaei</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Bang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Mahadevan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Khademullah</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Bedard</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Parfitt</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Woodin</surname><given-names>MA</given-names></name></person-group>
<year>2018</year>
<article-title>Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>115</volume>, <fpage>E1618</fpage>–<lpage>E1626</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1716871115</pub-id>)<pub-id pub-id-type="pmid">29382760</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dzhala</surname><given-names>VI</given-names></name>, <name name-style="western"><surname>Talos</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Sdrulla</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Brumback</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Mathews</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Benke</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Delpire</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name>, <name name-style="western"><surname>Staley</surname><given-names>KJ</given-names></name></person-group>
<year>2005</year>
<article-title>NKCC1 transporter facilitates seizures in the developing brain</article-title>. <source/>Nat. Med.
<volume>11</volume>, <fpage>1205</fpage>–<lpage>1213</lpage>. (<pub-id pub-id-type="doi">10.1038/nm1301</pub-id>)<pub-id pub-id-type="pmid">16227993</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palma</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2006</year>
<article-title>Anomalous levels of Cl<sup>−</sup> transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>103</volume>, <fpage>8465</fpage>–<lpage>8468</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0602979103</pub-id>)<pub-id pub-id-type="pmid">16709666</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cepeda-Prado</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Popp</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Stefanov</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Menalled</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Dow-Edwards</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>H</given-names></name></person-group>
<year>2012</year>
<article-title>R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>6456</fpage>–<lpage>6467</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0388-12.2012</pub-id>)<pub-id pub-id-type="pmid">22573668</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fusilli</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis</article-title>. <source/>Lancet Neurol.
<volume>17</volume>, <fpage>986</fpage>–<lpage>993</lpage>. (<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30294-1</pub-id>)<pub-id pub-id-type="pmid">30243861</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cloud</surname><given-names>LJ</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort</article-title>. <source/>Movement Disord.
<volume>27</volume>, <fpage>1797</fpage>–<lpage>1800</lpage>. (<pub-id pub-id-type="doi">10.1002/mds.25237</pub-id>)<pub-id pub-id-type="pmid">23124580</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>RJ</given-names></name></person-group>
<year>2009</year>
<article-title>Mouse models of Huntington's disease and methodological considerations for therapeutic trials</article-title>. <source/>Biochim. Biophys. Acta
<volume>1792</volume>, <fpage>506</fpage>–<lpage>520</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbadis.2009.04.001</pub-id>)<pub-id pub-id-type="pmid">19362590</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saudou</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Humbert</surname><given-names>S</given-names></name></person-group>
<year>2016</year>
<article-title>The biology of Huntingtin</article-title>. <source/>Neuron
<volume>89</volume>, <fpage>910</fpage>–<lpage>926</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2016.02.003</pub-id>)<pub-id pub-id-type="pmid">26938440</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Tabrizi</surname><given-names>SJ</given-names></name></person-group>
<year>2011</year>
<article-title>Huntington's disease: from molecular pathogenesis to clinical treatment</article-title>. <source/>Lancet Neurol.
<volume>10</volume>, <fpage>83</fpage>–<lpage>98</lpage>. (<pub-id pub-id-type="doi">10.1016/S1474-4422(10)70245-3</pub-id>)<pub-id pub-id-type="pmid">21163446</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Kronenbuerger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Margolis</surname><given-names>RL</given-names></name></person-group>
<year>2017</year>
<article-title>Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies</article-title>. <source/>Handb. Clin. Neurol.
<volume>144</volume>, <fpage>15</fpage>–<lpage>28</lpage>. (<pub-id pub-id-type="doi">10.1016/B978-0-12-801893-4.00002-X</pub-id>)<pub-id pub-id-type="pmid">28947113</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Glass</surname><given-names>CK</given-names></name></person-group>
<year>2015</year>
<article-title>The choreography of neuroinflammation in Huntington's disease</article-title>. <source/>Trends Immunol.
<volume>36</volume>, <fpage>364</fpage>–<lpage>373</lpage>. (<pub-id pub-id-type="doi">10.1016/j.it.2015.04.007</pub-id>)<pub-id pub-id-type="pmid">26001312</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunah</surname><given-names>AW</given-names></name><etal>et al.</etal></person-group>
<year>2002</year>
<article-title>Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease</article-title>. <source/>Science
<volume>296</volume>, <fpage>2238</fpage>–<lpage>2243</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1072613</pub-id>)<pub-id pub-id-type="pmid">11988536</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuccato</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>2003</year>
<article-title>Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes</article-title>. <source/>Nat. Genet.
<volume>35</volume>, <fpage>76</fpage>–<lpage>83</lpage>. (<pub-id pub-id-type="doi">10.1038/ng1219</pub-id>)<pub-id pub-id-type="pmid">12881722</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valor</surname><given-names>LM</given-names></name></person-group>
<year>2015</year>
<article-title>Transcription, epigenetics and ameliorative strategies in Huntington's disease: a genome-wide perspective</article-title>. <source/>Mol. Neurobiol.
<volume>51</volume>, <fpage>406</fpage>–<lpage>423</lpage>. (<pub-id pub-id-type="doi">10.1007/s12035-014-8715-8</pub-id>)<pub-id pub-id-type="pmid">24788684</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>CJ</given-names></name></person-group>
<year>2007</year>
<article-title>In silico comparative genomic analysis of GABAA receptor transcriptional regulation</article-title>. <source/>BMC Genomics
<volume>8</volume>, <fpage>203</fpage> (<pub-id pub-id-type="doi">10.1186/1471-2164-8-203</pub-id>)<pub-id pub-id-type="pmid">17603907</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berglund</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Augustine</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Liedtke</surname><given-names>W</given-names></name></person-group>
<year>2009</year>
<article-title>Novel repression of Kcc2 transcription by REST-RE-1 controls developmental switch in neuronal chloride</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>14 652</fpage>–<lpage>14 662</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2934-09.2009</pub-id>)<pub-id pub-id-type="pmid">19129380</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twelvetrees</surname><given-names>AE</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin</article-title>. <source/>Neuron
<volume>65</volume>, <fpage>53</fpage>–<lpage>65</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2009.12.007</pub-id>)<pub-id pub-id-type="pmid">20152113</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirasaki</surname><given-names>DI</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Network organization of the huntingtin proteomic interactome in mammalian brain</article-title>. <source/>Neuron
<volume>75</volume>, <fpage>41</fpage>–<lpage>57</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2012.05.024</pub-id>)<pub-id pub-id-type="pmid">22794259</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Culver</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Savas</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zeitlin</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>JR</given-names><suffix>III</suffix></name>, <name name-style="western"><surname>Tanese</surname><given-names>N</given-names></name></person-group>
<year>2012</year>
<article-title>Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>21 599</fpage>–<lpage>21 614</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M112.359307</pub-id>)<pub-id pub-id-type="pmid">22069324</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>YS</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease</article-title>. <source/>J. Clin. Invest.
<volume>121</volume>, <fpage>1519</fpage>–<lpage>1523</lpage>. (<pub-id pub-id-type="doi">10.1172/JCI43220</pub-id>)<pub-id pub-id-type="pmid">21403395</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morales-Aza</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Chillingworth</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Donaldson</surname><given-names>LF</given-names></name></person-group>
<year>2004</year>
<article-title>Inflammation alters cation chloride cotransporter expression in sensory neurons</article-title>. <source/>Neurobiol. Dis.
<volume>17</volume>, <fpage>62</fpage>–<lpage>69</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2004.05.010</pub-id>)<pub-id pub-id-type="pmid">15350966</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Woitecki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Franjic-Wurtz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gensch</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mohrlen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Frings</surname><given-names>S</given-names></name></person-group>
<year>2008</year>
<article-title>Modulation of chloride homeostasis by inflammatory mediators in dorsal root ganglion neurons</article-title>. <source/>Mol. Pain
<volume>4</volume>, <fpage>32</fpage> (<pub-id pub-id-type="doi">10.1186/1744-8069-4-32</pub-id>)<pub-id pub-id-type="pmid">18700020</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradford</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>XJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name></person-group>
<year>2009</year>
<article-title>Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>22 480</fpage>–<lpage>22 485</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0911503106</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Chern</surname><given-names>Y</given-names></name></person-group>
<year>2013</year>
<article-title>A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease</article-title>. <source/>Hum. Mol. Genet.
<volume>22</volume>, <fpage>1826</fpage>–<lpage>1842</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/ddt036</pub-id>)<pub-id pub-id-type="pmid">23372043</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sapp</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kegel</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Aronin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hashikawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Uchiyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tohyama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bhide</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Vonsattel</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>DiFiglia</surname><given-names>M</given-names></name></person-group>
<year>2001</year>
<article-title>Early and progressive accumulation of reactive microglia in the Huntington disease brain</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>60</volume>, <fpage>161</fpage>–<lpage>172</lpage>. (<pub-id pub-id-type="doi">10.1093/jnen/60.2.161</pub-id>)<pub-id pub-id-type="pmid">11273004</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotti</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors</article-title>. <source/>Nat. Neurosci.
<volume>17</volume>, <fpage>513</fpage>–<lpage>521</lpage>. (<pub-id pub-id-type="doi">10.1038/nn.3668</pub-id>)<pub-id pub-id-type="pmid">24584051</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Pavese</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gerhard</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tabrizi</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Piccini</surname><given-names>P</given-names></name></person-group>
<year>2007</year>
<article-title>Microglial activation in presymptomatic Huntington's disease gene carriers</article-title>. <source/>Brain
<volume>130</volume>, <fpage>1759</fpage>–<lpage>1766</lpage>. (<pub-id pub-id-type="doi">10.1093/brain/awm044</pub-id>)<pub-id pub-id-type="pmid">17400599</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franciosi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ryu</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Shim</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Connolly</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hayden</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>McLarnon</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Leavitt</surname><given-names>BR</given-names></name></person-group>
<year>2012</year>
<article-title>Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease</article-title>. <source/>Neurobiol. Dis.
<volume>45</volume>, <fpage>438</fpage>–<lpage>449</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2011.09.003</pub-id>)<pub-id pub-id-type="pmid">21946335</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvestroni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Faull</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Strand</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Moller</surname><given-names>T</given-names></name></person-group>
<year>2009</year>
<article-title>Distinct neuroinflammatory profile in post-mortem human Huntington's disease</article-title>. <source/>NeuroReport
<volume>20</volume>, <fpage>1098</fpage>–<lpage>1103</lpage>. (<pub-id pub-id-type="doi">10.1097/WNR.0b013e32832e34ee</pub-id>)<pub-id pub-id-type="pmid">19590393</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>. <source/>Nature
<volume>541</volume>, <fpage>481</fpage>–<lpage>487</lpage>. (<pub-id pub-id-type="doi">10.1038/nature21029</pub-id>)<pub-id pub-id-type="pmid">28099414</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prestridge</surname><given-names>DS</given-names></name></person-group>
<year>1995</year>
<article-title>Predicting Pol II promoter sequences using transcription factor binding sites</article-title>. <source/>J. Mol. Biol.
<volume>249</volume>, <fpage>923</fpage>–<lpage>932</lpage>. (<pub-id pub-id-type="doi">10.1006/jmbi.1995.0349</pub-id>)<pub-id pub-id-type="pmid">7791218</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farre</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Roset</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Huerta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Adsuara</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Rosello</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Alba</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Messeguer</surname><given-names>X</given-names></name></person-group>
<year>2003</year>
<article-title>Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN</article-title>. <source/>Nucleic Acids Res.
<volume>31</volume>, <fpage>3651</fpage>–<lpage>3653</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkg605</pub-id>)<pub-id pub-id-type="pmid">12824386</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messeguer</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Escudero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Farre</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nunez</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alba</surname><given-names>MM</given-names></name></person-group>
<year>2002</year>
<article-title>PROMO: detection of known transcription regulatory elements using species-tailored searches</article-title>. <source/>Bioinformatics
<volume>18</volume>, <fpage>333</fpage>–<lpage>334</lpage>. (<pub-id pub-id-type="doi">10.1093/bioinformatics/18.2.333</pub-id>)<pub-id pub-id-type="pmid">11847087</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayakumar</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Ruiz-Cordero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bregy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bethea</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Bramlett</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Norenberg</surname><given-names>MD</given-names></name></person-group>
<year>2014</year>
<article-title>Activation of NF-kappaB mediates astrocyte swelling and brain edema in traumatic brain injury</article-title>. <source/>J. Neurotrauma
<volume>31</volume>, <fpage>1249</fpage>–<lpage>1257</lpage>. (<pub-id pub-id-type="doi">10.1089/neu.2013.3169</pub-id>)<pub-id pub-id-type="pmid">24471369</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name></person-group>
<year>2017</year>
<article-title>Astaxanthin protects astrocytes against trauma-induced apoptosis through inhibition of NKCC1 expression via the NF-kappaB signaling pathway</article-title>. <source/>BMC Neurosci.
<volume>18</volume>, <fpage>42</fpage> (<pub-id pub-id-type="doi">10.1186/s12868-017-0358-z</pub-id>)<pub-id pub-id-type="pmid">28490320</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Downer</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>O'Leary</surname><given-names>OF</given-names></name></person-group>
<year>2016</year>
<article-title>Inhibiting neuroinflammation: the role and therapeutic potential of GABA in neuro-immune interactions</article-title>. <source/>Brain Behav. Immun.
<volume>54</volume>, <fpage>260</fpage>–<lpage>277</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbi.2016.02.001</pub-id>)<pub-id pub-id-type="pmid">26851553</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olmos</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Llado</surname><given-names>J</given-names></name></person-group>
<year>2014</year>
<article-title>Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity</article-title>. <source/>Mediators Inflamm.
<volume>2014</volume>, <fpage>861231</fpage> (<pub-id pub-id-type="doi">10.1155/2014/861231</pub-id>)<pub-id pub-id-type="pmid">24966471</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stellwagen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Beattie</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Malenka</surname><given-names>RC</given-names></name></person-group>
<year>2005</year>
<article-title>Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>3219</fpage>–<lpage>3228</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4486-04.2005</pub-id>)<pub-id pub-id-type="pmid">15788779</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pribiag</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stellwagen</surname><given-names>D</given-names></name></person-group>
<year>2013</year>
<article-title>TNF-alpha downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABA(A) receptors</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>15 879</fpage>–<lpage>15 893</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0530-13.2013</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuoka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tokunaga</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Miki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tachibana</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Noguchi</surname><given-names>K</given-names></name></person-group>
<year>1998</year>
<article-title>Change in mRNAs for neuropeptides and the GABA(A) receptor in dorsal root ganglion neurons in a rat experimental neuropathic pain model</article-title>. <source/>Pain
<volume>78</volume>, <fpage>13</fpage>–<lpage>26</lpage>. (<pub-id pub-id-type="doi">10.1016/S0304-3959(98)00111-0</pub-id>)<pub-id pub-id-type="pmid">9822208</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Suh</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Huh</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Ihn</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name></person-group>
<year>1998</year>
<article-title>Central GABAA and GABAB receptor modulation of basal and stress-induced plasma interleukin-6 levels in mice</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>287</volume>, <fpage>144</fpage>–<lpage>149</lpage>.<pub-id pub-id-type="pmid">9765333</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheridan</surname><given-names>GK</given-names></name>, <name name-style="western"><surname>Pickering</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Twomey</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Moynagh</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>O'Connor</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>KJ</given-names></name></person-group>
<year>2007</year>
<article-title>NF-kappaB activity in distinct neural subtypes of the rat hippocampus: Influence of time and GABA antagonism in acute slice preparations</article-title>. <source/>Learn. Mem.
<volume>14</volume>, <fpage>525</fpage>–<lpage>532</lpage>. (<pub-id pub-id-type="doi">10.1101/lm.590007</pub-id>)<pub-id pub-id-type="pmid">17686946</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faideau</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title><italic>In vivo</italic> expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>3053</fpage>–<lpage>3067</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/ddq212</pub-id>)<pub-id pub-id-type="pmid">20494921</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice</article-title>. <source/>Nat. Neurosci.
<volume>17</volume>, <fpage>694</fpage>–<lpage>703</lpage>. (<pub-id pub-id-type="doi">10.1038/nn.3691</pub-id>)<pub-id pub-id-type="pmid">24686787</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaenisch</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liebmann</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Guenther</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hubner</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Frahm</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Witte</surname><given-names>OW</given-names></name></person-group>
<year>2016</year>
<article-title>Reduced tonic inhibition after stroke promotes motor performance and epileptic seizures</article-title>. <source/>Sci. Rep.
<volume>6</volume>, <fpage>26173</fpage> (<pub-id pub-id-type="doi">10.1038/srep26173</pub-id>)<pub-id pub-id-type="pmid">27188341</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Deeb</surname><given-names>TZ</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>SJ</given-names></name></person-group>
<year>2011</year>
<article-title>NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents</article-title>. <source/>Nat. Neurosci.
<volume>14</volume>, <fpage>736</fpage>–<lpage>743</lpage>. (<pub-id pub-id-type="doi">10.1038/nn.2806</pub-id>)<pub-id pub-id-type="pmid">21532577</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangroo Thrane</surname><given-names>V</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering</article-title>. <source/>Nat. Med.
<volume>19</volume>, <fpage>1643</fpage>–<lpage>1648</lpage>. (<pub-id pub-id-type="doi">10.1038/nm.3400</pub-id>)<pub-id pub-id-type="pmid">24240184</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Horta</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease</article-title>. <source/>Parkinsonism Relat. Disord.
<volume>25</volume>, <fpage>58</fpage>–<lpage>64</lpage>. (<pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.02.008</pub-id>)<pub-id pub-id-type="pmid">26898966</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Duijn</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)</article-title>. <source/>J. Neurol. Neurosurg. Psychiatry
<volume>85</volume>, <fpage>1411</fpage>–<lpage>1418</lpage>. (<pub-id pub-id-type="doi">10.1136/jnnp-2013-307343</pub-id>)<pub-id pub-id-type="pmid">24828898</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sipila</surname><given-names>JO</given-names></name>, <name name-style="western"><surname>Soilu-Hanninen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Majamaa</surname><given-names>K</given-names></name></person-group>
<year>2016</year>
<article-title>Comorbid epilepsy in Finnish patients with adult-onset Huntington's disease</article-title>. <source/>BMC Neurol.
<volume>16</volume>, <fpage>24</fpage> (<pub-id pub-id-type="doi">10.1186/s12883-016-0545-z</pub-id>)<pub-id pub-id-type="pmid">26860086</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantor</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Varga</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Morton</surname><given-names>AJ</given-names></name></person-group>
<year>2016</year>
<article-title>A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice</article-title>. <source/>Neuropharmacology
<volume>105</volume>, <fpage>298</fpage>–<lpage>307</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.01.027</pub-id>)<pub-id pub-id-type="pmid">26805423</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallier</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Maywood</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chesham</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Inyushkin</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Dyball</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hastings</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Morton</surname><given-names>AJ</given-names></name></person-group>
<year>2007</year>
<article-title>Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>7869</fpage>–<lpage>7878</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0649-07.2007</pub-id>)<pub-id pub-id-type="pmid">17634381</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Deshmukh</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lal Sharma</surname><given-names>P</given-names></name></person-group>
<year>2014</year>
<article-title>Role of neurosteroids in experimental 3-nitropropionic acid induced neurotoxicity in rats</article-title>. <source/>Eur. J. Pharmacol.
<volume>723</volume>, <fpage>38</fpage>–<lpage>45</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ejphar.2013.11.036</pub-id>)<pub-id pub-id-type="pmid">24333475</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease</article-title>. <source/>Neurobiol. Dis.
<volume>30</volume>, <fpage>293</fpage>–<lpage>302</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nbd.2008.01.014</pub-id>)<pub-id pub-id-type="pmid">18395459</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowley</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Madsen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Schousboe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>White</surname><given-names>HS</given-names></name></person-group>
<year>2012</year>
<article-title>Glutamate and GABA synthesis, release, transport and metabolism as targets for seizure control</article-title>. <source/>Neurochem. Int.
<volume>61</volume>, <fpage>546</fpage>–<lpage>558</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuint.2012.02.013</pub-id>)<pub-id pub-id-type="pmid">22365921</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadros</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Khalifa</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Abdel-Naim</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Arafa</surname><given-names>HM</given-names></name></person-group>
<year>2005</year>
<article-title>Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>82</volume>, <fpage>574</fpage>–<lpage>582</lpage>. (<pub-id pub-id-type="doi">10.1016/j.pbb.2005.10.018</pub-id>)<pub-id pub-id-type="pmid">16337998</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Chase</surname><given-names>TN</given-names></name>, <name name-style="western"><surname>Denaro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hare</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Tamminga</surname><given-names>CA</given-names></name></person-group>
<year>1983</year>
<article-title>THIP treatment of Huntington's disease</article-title>. <source/>Neurology
<volume>33</volume>, <fpage>637</fpage>–<lpage>639</lpage>. (<pub-id pub-id-type="doi">10.1212/WNL.33.5.637</pub-id>)<pub-id pub-id-type="pmid">6221200</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoulson</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Charlton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Joynt</surname><given-names>RJ</given-names></name></person-group>
<year>1978</year>
<article-title>Huntington's disease: treatment with muscimol, a GABA-mimetic drug</article-title>. <source/>Ann. Neurol.
<volume>4</volume>, <fpage>279</fpage>–<lpage>284</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.410040316</pub-id>)<pub-id pub-id-type="pmid">152602</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scigliano</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Giovannini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Girotti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Grassi</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Caraceni</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schechter</surname><given-names>PJ</given-names></name></person-group>
<year>1984</year>
<article-title>Gamma-vinyl GABA treatment of Huntington's disease</article-title>. <source/>Neurology
<volume>34</volume>, <fpage>94</fpage>–<lpage>96</lpage>. (<pub-id pub-id-type="doi">10.1212/WNL.34.1.94</pub-id>)<pub-id pub-id-type="pmid">6228746</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TA</given-names></name></person-group>
<year>2001</year>
<article-title>Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment</article-title>. <source/>Br. J. Biomed. Sci.
<volume>58</volume>, <fpage>111</fpage>–<lpage>121</lpage>.<pub-id pub-id-type="pmid">11440203</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kooy</surname><given-names>RF</given-names></name></person-group>
<year>2015</year>
<article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders</article-title>. <source/>Neuron
<volume>86</volume>, <fpage>1119</fpage>–<lpage>1130</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.042</pub-id>)<pub-id pub-id-type="pmid">26050032</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Benham</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Rudolph</surname><given-names>U</given-names></name></person-group>
<year>2018</year>
<article-title>An emerging circuit pharmacology of GABAA receptors</article-title>. <source/>Trends Pharmacol. Sci.
<volume>39</volume>, <fpage>710</fpage>–<lpage>732</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tips.2018.04.003</pub-id>)<pub-id pub-id-type="pmid">29903580</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepers</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Raymond</surname><given-names>LA</given-names></name></person-group>
<year>2014</year>
<article-title>Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease</article-title>. <source/>Drug Discov. Today
<volume>19</volume>, <fpage>990</fpage>–<lpage>996</lpage>. (<pub-id pub-id-type="doi">10.1016/j.drudis.2014.02.006</pub-id>)<pub-id pub-id-type="pmid">24603212</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiner</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia</article-title>. <source/>Movement Disord.
<volume>28</volume>, <fpage>1691</fpage>–<lpage>1699</lpage>. (<pub-id pub-id-type="doi">10.1002/mds.25624</pub-id>)<pub-id pub-id-type="pmid">24014043</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nohria</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Giller</surname><given-names>E</given-names></name></person-group>
<year>2007</year>
<article-title>Ganaxolone</article-title>. <source/>Neurotherapeutics
<volume>4</volume>, <fpage>102</fpage>–<lpage>105</lpage>. (<pub-id pub-id-type="doi">10.1016/j.nurt.2006.11.003</pub-id>)<pub-id pub-id-type="pmid">17199022</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deidda</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Parrini</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Naskar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bozarth</surname><given-names>IF</given-names></name>, <name name-style="western"><surname>Contestabile</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cancedda</surname><given-names>L</given-names></name></person-group>
<year>2015</year>
<article-title>Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome</article-title>. <source/>Nat. Med.
<volume>21</volume>, <fpage>318</fpage>–<lpage>326</lpage>. (<pub-id pub-id-type="doi">10.1038/nm.3827</pub-id>)<pub-id pub-id-type="pmid">25774849</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Nomura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Contractor</surname><given-names>A</given-names></name></person-group>
<year>2014</year>
<article-title>The developmental switch in GABA polarity is delayed in fragile X mice</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>446</fpage>–<lpage>450</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4447-13.2014</pub-id>)<pub-id pub-id-type="pmid">24403144</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyde</surname><given-names>TM</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>11 088</fpage>–<lpage>11 095</lpage>. (<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1234-11.2011</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia</article-title>. <source/>Cell
<volume>148</volume>, <fpage>1051</fpage>–<lpage>1064</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2011.12.037</pub-id>)<pub-id pub-id-type="pmid">22385968</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyzio</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2014</year>
<article-title>Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring</article-title>. <source/>Science
<volume>343</volume>, <fpage>675</fpage>–<lpage>679</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1247190</pub-id>)<pub-id pub-id-type="pmid">24503856</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lozovaya</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease</article-title>. <source/>Nat. Commun.
<volume>9</volume>, <fpage>1422</fpage> (<pub-id pub-id-type="doi">10.1038/s41467-018-03802-y</pub-id>)<pub-id pub-id-type="pmid">29651049</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulte</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Wierenga</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Bruining</surname><given-names>H</given-names></name></person-group>
<year>2018</year>
<article-title>Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>90</volume>, <fpage>260</fpage>–<lpage>271</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.05.001</pub-id>)<pub-id pub-id-type="pmid">29729285</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Ari</surname><given-names>Y</given-names></name></person-group>
<year>2017</year>
<article-title>NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders</article-title>. <source/>Trends Neurosci.
<volume>40</volume>, <fpage>536</fpage>–<lpage>554</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tins.2017.07.001</pub-id>)<pub-id pub-id-type="pmid">28818303</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Romermann</surname><given-names>K</given-names></name>, <name name-style="western"><surname>MacAulay</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Loscher</surname><given-names>W</given-names></name></person-group>
<year>2018</year>
<article-title>Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B</article-title>. <source/>Sci. Rep.
<volume>8</volume>, <fpage>9877</fpage> (<pub-id pub-id-type="doi">10.1038/s41598-018-27995-w</pub-id>)<pub-id pub-id-type="pmid">29959396</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romermann</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fedrowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hampel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaczmarek</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tollner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Erker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sweet</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Loscher</surname><given-names>W</given-names></name></person-group>
<year>2017</year>
<article-title>Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain</article-title>. <source/>Neuropharmacology
<volume>117</volume>, <fpage>182</fpage>–<lpage>194</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.02.006</pub-id>)<pub-id pub-id-type="pmid">28192112</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpire</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>CD</given-names></name></person-group>
<year>2016</year>
<article-title>Challenges of finding novel drugs targeting the K-Cl cotransporter</article-title>. <source/>ACS Chem. Neurosci.
<volume>7</volume>, <fpage>1624</fpage>–<lpage>1627</lpage>. (<pub-id pub-id-type="doi">10.1021/acschemneuro.6b00366</pub-id>)<pub-id pub-id-type="pmid">27998063</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Reactivation of dormant relay pathways in injured spinal cord by KCC2 manipulations</article-title>. <source/>Cell
<volume>174</volume>, <fpage>521</fpage>–<lpage>535 e513</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2018.06.005</pub-id>)<pub-id pub-id-type="pmid">30033363</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagnon</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Chloride extrusion enhancers as novel therapeutics for neurological diseases</article-title>. <source/>Nat. Med.
<volume>19</volume>, <fpage>1524</fpage>–<lpage>1528</lpage>. (<pub-id pub-id-type="doi">10.1038/nm.3356</pub-id>)<pub-id pub-id-type="pmid">24097188</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alessi</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Khanna</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hochdorfer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kahle</surname><given-names>KT</given-names></name></person-group>
<year>2014</year>
<article-title>The WNK-SPAK/OSR1 pathway: master regulator of cation–chloride cotransporters</article-title>. <source/>Sci. Signaling
<volume>7</volume>, <fpage>re3</fpage> (<pub-id pub-id-type="doi">10.1126/scisignal.2005365</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kikuchi</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters</article-title>. <source/>J. Am. Soc. Nephrol.
<volume>26</volume>, <fpage>1525</fpage>–<lpage>1536</lpage>. (<pub-id pub-id-type="doi">10.1681/ASN.2014060560</pub-id>)<pub-id pub-id-type="pmid">25377078</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy</article-title>. <source/>Biochem. J.
<volume>455</volume>, <fpage>339</fpage>–<lpage>345</lpage>. (<pub-id pub-id-type="doi">10.1042/BJ20130597</pub-id>)<pub-id pub-id-type="pmid">23981180</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conway</surname><given-names>LC</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation</article-title>. <source/>J. Biol. Chem.
<volume>292</volume>, <fpage>21 253</fpage>–<lpage>21 263</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M117.817841</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB180165C151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steed</surname><given-names>PM</given-names></name><etal>et al.</etal></person-group>
<year>2003</year>
<article-title>Inactivation of TNF signaling by rationally designed dominant-negative TNF variants</article-title>. <source/>Science
<volume>301</volume>, <fpage>1895</fpage>–<lpage>1898</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1081297</pub-id>)<pub-id pub-id-type="pmid">14512626</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YR</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Chern</surname><given-names>Y</given-names></name></person-group>
<year>2014</year>
<article-title>Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease</article-title>. <source/>Hum. Mol. Genet.
<volume>23</volume>, <fpage>4328</fpage>–<lpage>4344</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/ddu151</pub-id>)<pub-id pub-id-type="pmid">24698979</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCoy</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Tansey</surname><given-names>MG</given-names></name></person-group>
<year>2008</year>
<article-title>TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease</article-title>. <source/>J. Neuroinflammation
<volume>5</volume>, <fpage>45</fpage> (<pub-id pub-id-type="doi">10.1186/1742-2094-5-45</pub-id>)<pub-id pub-id-type="pmid">18925972</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucin</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group>
<year>2009</year>
<article-title>Immune activation in brain aging and neurodegeneration: too much or too little?</article-title>
<source/>Neuron
<volume>64</volume>, <fpage>110</fpage>–<lpage>122</lpage>. (<pub-id pub-id-type="doi">10.1016/j.neuron.2009.08.039</pub-id>)<pub-id pub-id-type="pmid">19840553</pub-id></mixed-citation>
</ref>
<ref id="RSOB180165C155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyss-Coray</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mucke</surname><given-names>L</given-names></name></person-group>
<year>2002</year>
<article-title>Inflammation in neurodegenerative disease--a double-edged sword</article-title>. <source/>Neuron
<volume>35</volume>, <fpage>419</fpage>–<lpage>432</lpage>. (<pub-id pub-id-type="doi">10.1016/S0896-6273(02)00794-8</pub-id>)<pub-id pub-id-type="pmid">12165466</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>